research in autism spectrum disorders quartile

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• HHS Author Manuscripts

From the CDC: Understanding Autism Spectrum Disorder

Deborah christensen.

Centers for Disease Control and Prevention, Atlanta

Jennifer Zubler

Eagle Global Scientific, San Antonio, TX

Autism spectrum disorder (ASD) is a condition characterized by impaired social communication as well as restricted and repetitive behaviors. It is considered a neurodevelopmental disorder because it is associated with neurologic changes that may begin in prenatal or early postnatal life, alters the typical pattern of child development, and produces chronic signs and symptoms that usually manifest in early childhood and have potential long-term consequences. In past decades, autism was conceptualized as a strictly defined set of behaviors, usually accompanied by intellectual impairment. Today, it is recognized as a spectrum, ranging from mild to severe, in which behaviors vary substantially and the majority of children who fall on the spectrum have average to above average intellectual ability. Here, the authors discuss the risk factors for ASD, its epidemiology, common concurrent conditions, evaluation, diagnosis, treatments, and outcomes.

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that typically manifests in early childhood as impaired social communication and restricted, repetitive behaviors and falls on a spectrum ranging from mild to severe. 1 For example, some people with ASD are nonverbal or speak only in simple sentences, while others are verbally skilled but have problems with social communication and pragmatic language, such that they respond inappropriately in conversation, misunderstand nonverbal communication, or lack age-appropriate competency to establish friendships. People with ASD may have difficulty adapting to changes in their routine or environment. Their interests, which are typically intense, may be limited. Some display stereotyped, repetitive motor movements or unusual sensory responses. Current diagnostic criteria for ASD can be found in the Diagnostic and Statistical Manual of Mental Disorders , fifth edition. 1

RISK FACTORS

ASD etiology is not completely understood, but multiple factors likely contribute to ASD development. 2 Neurologic changes that result in ASD may begin in prenatal and early postnatal life, 3 and genetic factors (both rare and common variants) are a source of population variation in ASD-related behaviors. 4 , 5

Sibling recurrence risk.

Studies have reported that roughly 15% to 20% of younger siblings of children with ASD meet the diagnostic criteria for ASD themselves. 6 , 7 Concordance is higher among monozygotic compared with dizygotic twins. 8 , 9

Other prenatal and perinatal risk factors have been identified, including

• prenatal exposure to valproic acid 10 or thalidomide, 11 and rubella infection. 12
• advanced parental age. 13 , 14
• maternal gestational diabetes and bleeding. 13
• neonatal complications, including low birth weight and small size for gestational age. 15
• preterm birth. 16

Although there’s evidence that any of these factors, which can negatively affect prenatal and perinatal health, may increase the risk of ASD, no single prenatal or perinatal factor has been found to have more than a modest association with ASD. 15 Additional reviews and meta-analyses of research on ASD risk factors have been published. 17 – 19 Research into risk factors for ASD is ongoing, including through such case–control studies as the Centers for Disease Control and Prevention (CDC) Study to Explore Early Development (SEED; see www.cdc.gov/ncbddd/autism/seed.html ). Studies have shown that there is no link between receiving vaccines and developing ASD, as is discussed in the evidence-based meta-analysis of case–control and cohort studies by Taylor and colleagues. 20 Additional information on vaccine safety is available from the CDC at www.cdc.gov/vaccinesafety/concerns/autism.html .

EPIDEMIOLOGY

Recent national surveys suggest that 2% to 3% of children ages three through 17 have a current or previous diagnosis of ASD. 21 , 22 A review of data from 2000 through 2014 on eight-year-old children in selected U.S. communities by the CDC’s Autism and Developmental Disabilities Monitoring (ADDM) Network showed that ASD prevalence estimates rose more than 150% over this period, from 6.7 per 1,000 in 2000 to 16.8 per 1,000 in 2014. 23

Sex differences.

CDC data show that ASD prevalence is four times greater in boys than in girls. 23 Higher prevalence among boys may be related to differences in biological susceptibility to ASD 24 or to less frequent or incomplete identification of ASD in girls because girls with ASD have less well-recognized symptom profiles or higher intellectual ability, better language skills, and perceived better social skills. 25

Racial/ethnic differences.

Historically, CDC surveillance reports had estimated higher ASD prevalence among white children compared with both Black and Hispanic children, possibly because of a failure to identify ASD among children across all racial and ethnic groups. Although ASD prevalence estimates continue to be higher among white than among Black and Hispanic children, the disparity has narrowed in recent years, possibly as a result of more effective outreach directed at racial and ethnic minority communities and improved access to diagnostic services. 23 , 26

Other contributing factors to the recent rise in estimated ASD prevalence include

• changes in ASD diagnostic criteria, clinical practices for identifying and diagnosing children with developmental delays, and reporting practices. 27 – 30
• improved access to ASD services through better insurance coverage. 30 – 32
• the inclusion of children with high intellectual ability and few or mild ASD symptoms. 26 , 28

The heterogeneity of ASD prevalence estimates across geographic areas 26 further supports the premise that regional differences in evaluation, diagnosis, clinical and reporting practices, and service access may affect calculated prevalence.

Prevalence trends by state.

The CDC has recently introduced an Autism Data Visualization Tool (see www.cdc.gov/ncbddd/autism/data ), which provides information about trends in ASD prevalence by state.

ASD in adults.

The CDC does not collect prevalence data on ASD in adults; however a population-based survey of adults in the United Kingdom (UK) estimated that approximately 1% met the study criteria for ASD, though most had never been formally diagnosed. 33 A follow-up analysis of these data combined with data collected from participants in the Intellectual Disability Case Register study found a similar combined prevalence rate (1.1%) among adults. 34 While ASD is usually diagnosed in childhood, some people first seek diagnosis in adulthood. Another UK study reported on 255 adults referred to the Autism Diagnostic Research Centre for neuropsychological assessment, 100 of whom were subsequently diagnosed with ASD. 35 Only four of these had a learning disability, as identified through the education system or a recent diagnosis (intelligence quotient [IQ] below 70). It’s not clear why those found to have ASD were not diagnosed earlier in life, but the researchers suggest that comorbid psychiatric diagnoses, which affected 58%, may have been factors, as psychiatric conditions such as anxiety and depression may have concealed ASD traits, delaying appropriate referral.

COMMON CONCURRENT CONDITIONS

Although the proportion of children identified with ASD and concurrent intellectual disability has declined over time, 26 suggesting improved identification of ASD in children with a high level of intellectual ability, a substantial proportion of people with ASD have concurrent intellectual disability. The most recent CDC data indicate that nearly one-third of eight-year-old children with ASD had an IQ within the range of intellectual disability (70 or below). 23

Other conditions that commonly occur with ASD include the following 36 :

• motor abnormalities, up to 79%
• attention deficit–hyperactivity disorder (ADHD), 28% to 44%
• gastrointestinal problems, 9% to 70%
• sleep problems, 50% to 80%
• aggressive behavior up to 68%
• anxiety, 42% to 56%
• depression, 12% to 70%

Associated pediatric conditions may include language delay, which occurs in up to 87% of three-year-olds with ASD, 37 or language regression (for example, children’s loss of their first few words or the development of severely impaired receptive–expressive language). 38 The risk of children with ASD developing epilepsy is greatest before the age of five and around the time of puberty and is greater in children with concurrent intellectual disability. 38

Neuropsychological and medical conditions, like the core features of ASD, may interfere with health, functioning, and relationships with family members and peers. The complex health care needs of people with ASD are best addressed through the medical home model of care, which is defined by the American Academy of Pediatrics (AAP; see https://medicalhomeinfo.aap.org/overview/Pages/Whatisthemedicalhome.aspx ). It is important to consider the person’s ASD and concurrent symptoms when conducting the history and physical evaluation, weighing treatment plans, and coordinating referrals for medical evaluation and care. 39

Risky behavioral issues.

In addition to associated medical conditions, people with ASD, particularly those with intellectual disability, may display risky behaviors such as self-injury (up to 50%) 36 and wandering, which has been reported by parents to occur in 37.7% of children who have both ASD and intellectual disability and 32.7% of children who have ASD without intellectual disability. 40 These behaviors may pose safety risks and generate considerable stress for both people with ASD and their families. The CDC provides safety information and resources on these and other potential dangers facing children with special needs at www.cdc.gov/ncbddd/disabilityandsafety/index.html . Families may also find toolkits from Autism Speaks to help them address challenging behaviors at www.autismspeaks.org/family-services/tool-kits/challenging-behaviors-tool-kit .

Nurses can help facilitate the coordination of treatment and safety approaches to challenging behaviors across home and community settings, including schools. Children with disabilities, including ASD, may be at increased risk for maltreatment, including neglect and physical abuse due to caregiver stress. Nurses should be prepared to recognize the signs of maltreatment and intervene when necessary. The Child Welfare Information Gateway, a service of the Children’s Bureau of the Administration for Children and Families at the U.S. Department of Health and Human Services (HHS), provides several resources for health care professionals on child maltreatment at www.childwelfare.gov/topics/preventing/developing/collaboration/professionals .

EVALUATION AND DIAGNOSIS

Diagnosing ASD can be challenging. To date, there is no biomarker or medical test that can distinguish those with ASD from those without.

To make a diagnosis, health care professionals rely on

• developmental history.
• parent, caregiver or self-reported responses to questions about ASD-related behaviors.
• direct observations of behavior.

Concerns initially reported by parents or caregivers of children with ASD often include

• language delays or unusual language usage.
• atypical social responses, such as difficulty initiating and sustaining interactions with other children or not responding to their name being called.
• repetitive behaviors, such as resistance to change.
• emotional and behavioral reactivity.

High-risk infants.

Data suggest that in high-risk infants (such as those who have an older sibling with ASD), the characteristic signs of ASD, such as social communication difficulties and repetitive behaviors, would usually become apparent between the ages of 18 and 36 months if they too have ASD. 3 However there may be prodromal behaviors that emerge in the first year, including difficulties with emotional regulation, 41 lack of response to bids for attention, inconsistent face gazing, and impaired motor control. 3 These signs may occur before the more easily recognized signs of ASD are apparent and may go unrecognized by parents, caregivers, and health care providers as potential indications of ASD. If, however; parents or caregivers raise concerns about these features with health care providers, it is important that providers take such observations seriously.

Early identification.

Efforts by public, pediatric, and other health organizations have focused on identifying children with ASD as early as possible to facilitate prompt treatment and behavioral intervention. CDC data have indicated that, for nearly all children with ASD, developmental concerns were documented by age 36 months, though there has been little progress in lowering the age of first ASD evaluation. 23 In some cases, ASD can reliably be diagnosed by age two, 37 though the stability of early diagnoses depends on the experience of the diagnosing clinician. Because children with ASD display both typical and atypical behaviors, an average health visit may not allow enough time to observe a child’s atypical behavior 42

Recommendations of the AAP.

To address the complexity of identifying ASD at an early age, the AAP recommends that all children receive ASD-specific screening with a standardized ASD screening test at ages 18 months and 24 months, or whenever concerns arise, and that developmental surveillance occur at each health visit. 39

Developmental surveillance, a flexible, ongoing process of assessment that continues as the child grows, involves the following steps 39 :

• asking parents or caregivers about concerns they may have regarding their child’s development, and listening and responding to these concerns
• obtaining and documenting the child’s developmental history
• noting findings based on informed observation of the child
• identifying potential risks, strengths, and supportive factors in the child’s medical and life history
• maintaining an accurate record of the surveillance and screening activities
• seeking input from and sharing observations and opinions with other health care professionals and educators outside the medical home (for example, with specialty providers or preschool teachers), with the consent of the patient or caregiver

Several online resources are available to assist health care providers in conducting developmental surveillance and to help parents of children in their practice track their child’s developmental milestones (see Developmental Surveillance Resources ).

Developmental Surveillance Resources

• Developmental Surveillance: What, Why and How, a video for health care providers from the American Academy of Pediatrics (AAP), available at: www.youtube.com/watch?v=sceYLUHhgnU&feature=youtu.be
• Milestone Tracker, a free app from the Centers for Disease Control and Prevention (CDC) that helps parents identify their children’s developmental milestones and provide support at every stage: www.cdc.gov/MilestoneTracker
• “Learn the Signs. Act Early” materials from the CDC, which include checklists and videos that can assist providers with developmental surveillance by encouraging parents to monitor their child’s development between health care visits and discuss any concerns: www.cdc.gov/ncbddd/actearly/milestones/index.html
• Autism Diagnosis Criteria: DSM-5 from Autism Speaks, available at: www.autismspeaks.org/autism-diagnosis-criteria-dsm-5
• Identifying and Caring for Children with Autism Spectrum Disorder: A Course for Pediatric Clinicians from the AAP, available at: https://shop.aap.org/identifying-and-caring-for-children-with-autism-spectrum-disorder-a-course-for-pediatric-clinicians

Nurses often play a critical role in surveillance, coordination, and championing the efforts of the health care team through the following actions:

• taking the developmental history
• eliciting parents’ concerns
• sharing observations of the child with the primary care provider
• distributing and scoring age-appropriate screens
• informing the primary care provider of screening results for discussion with the family
• submitting and following up on ordered referrals
• recognizing a pattern of early childhood development consistent with ASD in older children and adults, whose difficulty in developing and maintaining friendships, communicating, and understanding what behaviors are expected in school or on the job may suggest undiagnosed ASD
• identifying concurrent conditions that often affect people with ASD
• referring parents of children with ASD, or adults with ASD that was undiagnosed in childhood, to services and specialists

Early intervention and special education.

If ASD risk is indicated on a validated screening tool, or if the provider or parent is concerned the child might have ASD despite normal screening results, the child should be referred promptly for further developmental and medical evaluation as the screening tool may have produced a false negative or the child may have other developmental delays that should be addressed. 43 Children under age three can be referred to the state’s early intervention program (see www.cdc.gov/ncbddd/actearly/parents/states.html for information on early intervention). Patients ages three through 21 can, through the Individuals with Disabilities Education Act (IDEA), receive evaluations and services through their local school district’s special education program. Referral for further developmental evaluation, audiological testing, and assessment for early intervention or special education services can all occur simultaneously. Developmental evaluations may be completed by developmental and behavioral pediatricians, child neurologists, child psychologists, and child psychiatrists.

Currently, there is no curative treatment for ASD, but interventions may reduce troubling symptoms, improving cognition and function, thereby maximizing the ability of people with ASD to participate in the community. Treatment plans are usually multidisciplinary and tailored to the person’s unique strengths and challenges. Some interventions are parent mediated. Behavioral intervention strategies often include social skills training for children and adults and focus on reducing restricted interests and repetitive or challenging behaviors. Occupational, speech, and sensory integration therapy may also be helpful.

For providers who are inexperienced in treating patients with ASD, especially adult patients, it’s important to consider the patient’s ASD diagnosis as one of many variables that affect an individual and to learn how to adapt treatment to accommodate the patient’s strengths, challenges, and differences. 44

ADHD medications.

Although no medications have proven effective in treating the core symptoms of ASD, some may be helpful in reducing concurrent conditions. Medications used to treat ADHD, including methylphenidate (Ritalin and others), atomoxetine (Strattera), and guanfacine (Intuniv), have shown benefit in treating children who have ASD and concurrent ADHD, though they may be less effective and have more adverse effects in these children than in those with ADHD alone. 45 – 47

Two atypical antipsychotic medications, risperidone (Risperdal) and aripiprazole (Abilify), have been shown in randomized controlled trials to reduce irritability or agitation in children and adolescents with ASD, but patients taking these drugs should be monitored for adverse effects, including weight gain and sedation. 48 , 49

Individualized education programs (IEPs).

Children with ASD often have an IEP or a 504 plan through which they may receive behavioral, speech, or occupational therapy, and other services in the school setting. For information about IEPs, visit the IDEA website at https://sites.ed.gov/idea (go to Resources, then Topic Areas). Children with ASD may be taught in a self-contained or general education classroom, be placed in an inclusion classroom that combines elements of both, or spend part of the school day in a general education classroom and part in a self-contained or inclusion classroom.

School nurses may play a role in a child’s treatment plan. For example, they may need to administer medication or assess health problems. School nurses should be aware that children with ASD who experience health problems may have difficulty reporting symptoms of illness or maltreatment and may be challenged by changes in routine such as visiting the nurse’s office, undergoing physical examination, and interacting with unfamiliar staff.

Support for parents.

Providers can direct parents of children with ASD to their state’s free parent support organization, which can be found on the website of Family Voices, a national organization and grassroots network of families of children with special health care needs (see http://familyvoices.org/affiliates ). These state- or territory-based organizations link parents with local resources as well as other parents of children with special needs or developmental disabilities who reside in their community. Families may seek out complementary and alternative therapies and should be encouraged to share and discuss these with their child’s provider.

OUTCOMES IN ADOLESCENCE AND ADULTHOOD

Relatively little is known about how ASD affects outcomes in adulthood, such as level of independence, education, employment, social relationships, community integration, and health status. While for some with ASD, symptom severity decreases over time, 50 studies suggest that outcomes are often poor, especially in the domain of social functioning. 51 A 2012 analysis of data from a nationally representative survey of young adults with ASD, as well as parents and guardians, found that the overall rate of paid employment following high school among young adults with ASD was 55.1%. 52

Poorer health and shorter life spans.

There is evidence that adults with ASD have poorer health and shorter life spans than adults without ASD. 53 A medical record review conducted at a large northern California health care system reported that adults with recent ASD diagnoses had higher frequencies of seizures, hypertension, dyslipidemia, sleep disorders, and psychiatric conditions than sex-and age-matched controls. 54 Another study conducted in the same health care system reported that while utilization of health care services was higher for adults with ASD compared with adults with ADHD and adults with neither condition, women with ASD were less likely to receive gynecologic care and be screened for cervical cancer. 55 Premature mortality among adults with ASD is associated with a variety of medical conditions, including epilepsy, particularly in those with concurrent intellectual disability. 53 , 56 Substantially higher mortality from suicide has been found in people with ASD, especially women and those without concurrent intellectual disability. 53 , 57

Adolescent transition to adult medical care.

Pediatric nurses can help adolescents with ASD prepare for the transition to adult medical care. Adult primary care nurses should be aware of the increasing numbers of people diagnosed with ASD as children who are coming into adult medical care, in addition to those who were diagnosed in adulthood, both of whom will require assistance with medical management and referrals, as well as anticipatory guidance regarding health conditions. Got Transition ( www.gottransition.org ) provides toolkits and other resources for adolescents, young adults, parents, caregivers, and health care providers helping families with this transition.

BEYOND PATIENT CARE: NECESSARY NURSING RESEARCH

ASD is more commonly diagnosed today than it was in the past. In addition to teaching parents and caregivers about developmental milestones, conducting surveillance and screening, assisting with referrals, advocating for appropriate diagnoses, monitoring the effectiveness of treatment plans, and helping families navigate the complex systems of services and resources available for people with ASD, nurses should realize that there is a pressing need for research into interventions and services that can help support people with ASD in securing postsecondary education or training, participating in the workforce, obtaining housing, accessing transportation, and managing their health. A broad range of topics related to ASD outcomes and other issues relevant to primary care are covered in a recent HHS report to Congress, available at www.hhs.gov/sites/default/files/2017AutismReport.pdf .

The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.

For three additional continuing nursing education activities on the topic of autism, go to www.nursingcenter.com .

Contributor Information

Deborah Christensen, Centers for Disease Control and Prevention, Atlanta.

Jennifer Zubler, Eagle Global Scientific, San Antonio, TX.

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Article Menu

• Subscribe SciFeed
• Recommended Articles
• PubMed/Medline
• Google Scholar
• on Google Scholar
• Table of Contents

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

JSmol Viewer

Recent developments in autism genetic research: a scientometric review from 2018 to 2022.

1. Introduction

2. materials and methods, 2.1. data collection and conversion, 2.2. document co-citation analysis, 2.3. metrics, 3.1. structural properties of dca network, 3.2. documents with a citation burst, 4. discussion, 4.1. cluster #0: networks and pathways, 4.2. cluster #1: gut microbiota, 4.3. clusters #2 and #3: mouse models, 4.4. clusters #4 and #6: stem cell technology, 4.5. cluster #5: genomic architecture, 4.6. cluster #7: psychiatric disorder, 4.7. cluster #8: sex difference, 4.8. cluster #9: copy number variations (cnvs), 4.9. cluster #10: developmental perspectives, 4.10. cluster #14: antiseizure drug, 4.11. limitations and future recommendations, 5. conclusions, author contributions, institutional review board statement, informed consent statement, data availability statement, conflicts of interest, abbreviations.

• Rosanoff, A.J. A Theory of Personality Based Mainly on Psychiatric Experience. Psychol. Bull. 1920 , 17 , 281. [ Google Scholar ] [ CrossRef ]
• Kanner, L. Early infantile autism. J. Pediatr. 1944 , 25 , 211–217. [ Google Scholar ] [ CrossRef ]
• Volkmar, F.R.; Bregman, J.; Cohen, D.J.; Cicchetti, D.V. DSM-III and DSM-III-R diagnoses of autism. Am. J. Psychiatry 1988 , 145 , 1404–1408. [ Google Scholar ] [ PubMed ]
• Grzadzinski, R.; Huerta, M.; Lord, C. DSM-5 and Autism Spectrum Disorders (ASDs): An opportunity for identifying ASD subtypes. Mol. Autism 2013 , 4 , 12. [ Google Scholar ] [ CrossRef ]
• Chiarotti, F.; Venerosi, A. Epidemiology of Autism Spectrum Disorders: A review of worldwide prevalence estimates since 2014. Brain Sci. 2020 , 10 , 274. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Fombonne, E. Is there an epidemic of autism? Pediatrics 2001 , 107 , 411–412. [ Google Scholar ] [ CrossRef ]
• Randall, M.; Sciberras, E.; Brignell, A.; Ihsen, E.; Efron, D.; Dissanayake, C.; Williams, K. Autism Spectrum Disorder: Presentation and prevalence in a nationally representative Australian sample. Aust. N. Z. J. Psychiatry 2016 , 50 , 243–253. [ Google Scholar ] [ CrossRef ]
• Ouellette-Kuntz, H.; Coo, H.; Lam, M.; Breitenbach, M.M.; Hennessey, P.E.; Jackman, P.D.; Lewis, M.; Dewey, D.; Bernier, F.P.; Chung, A.M. The changing prevalence of autism in three regions of Canada. J. Autism Dev. Disord. 2014 , 44 , 120–136. [ Google Scholar ] [ CrossRef ]
• MAY, J.; Dunn, L. A preliminary study of inherited blood group antigens in families having an index case of early infantile autism. J. Hered. 1961 , 52 , 239–240. [ Google Scholar ] [ CrossRef ]
• Gayon, J. From Mendel to epigenetics: History of genetics. Comptes Rendus Biol. 2016 , 339 , 225–230. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Muhle, R.; Trentacoste, S.V.; Rapin, I. The genetics of autism. Pediatrics 2004 , 113 , e472–e486. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Geschwind, D.H. Genetics of Autism Spectrum Disorders. Trends Cogn. Sci. 2011 , 15 , 409–416. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Qiu, S.; Qiu, Y.; Li, Y.; Cong, X. Genetics of Autism Spectrum Disorder: An umbrella review of systematic reviews and meta-analyses. Transl. Psychiatry 2022 , 12 , 249. [ Google Scholar ] [ CrossRef ]
• Rylaarsdam, L.; Guemez-Gamboa, A. Genetic causes and modifiers of Autism Spectrum Disorder. Front. Cell. Neurosci. 2019 , 13 , 385. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Cataldo, I.; Azhari, A.; Esposito, G. A review of oxytocin and arginine-vasopressin receptors and their modulation of Autism Spectrum Disorder. Front. Mol. Neurosci. 2018 , 11 , 27. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Azhari, A.; Azizan, F.; Esposito, G. A systematic review of gut-immune-brain mechanisms in Autism Spectrum Disorder. Dev. Psychobiol. 2019 , 61 , 752–771. [ Google Scholar ] [ CrossRef ]
• Jahan, N.; Naveed, S.; Zeshan, M.; Tahir, M.A. How to conduct a systematic review: A narrative literature review. Cureus 2016 , 8 , e864. [ Google Scholar ] [ CrossRef ]
• Mulchenko, Z. Measurement of science. study of the development of science as an information process. In USAF Foreign Technology Division Translation AD735634 ; National Technical Information Service: Springfield, VA, USA, 1969. [ Google Scholar ]
• Börner, K.; Chen, C.; Boyack, K.W. Visualizing knowledge domains. Annu. Rev. Inf. Sci. Technol. 2003 , 37 , 179–255. [ Google Scholar ] [ CrossRef ]
• Junior, O.F. The Legacy of David Bohm in Physics—An Essay in Scientometry. In David Bohm ; Springer: Cham, Switzerland, 2019; pp. 223–240. [ Google Scholar ]
• Su, H.N.; Lee, P.C. Mapping knowledge structure by keyword co-occurrence: A first look at journal papers in Technology Foresight. Scientometrics 2010 , 85 , 65–79. [ Google Scholar ] [ CrossRef ]
• Cataldo, I.; Lieu, A.A.; Carollo, A.; Bornstein, M.H.; Gabrieli, G.; Lee, A.; Esposito, G. From the cradle to the web: The growth of “sharenting”—A scientometric perspective. Hum. Behav. Emerg. Technol. 2022 , 2022 , 5607422. [ Google Scholar ] [ CrossRef ]
• Aryadoust, V.; Zakaria, A.; Lim, M.H.; Chen, C. An extensive knowledge mapping review of measurement and validity in language assessment and SLA research. Front. Psychol. 2020 , 11 , 1941. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Chen, C. Science mapping: A systematic review of the literature. J. Data Inf. Sci. 2017 , 2 , 1–40. [ Google Scholar ] [ CrossRef ]
• Chen, C. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature. J. Am. Soc. Inf. Sci. Technol. 2006 , 57 , 359–377. [ Google Scholar ] [ CrossRef ]
• Chen, C. CiteSpace: A Practical Guide for Mapping Scientific Literature ; Nova Science Publishers: Hauppauge, NY, USA, 2016. [ Google Scholar ]
• Small, H. Co-citation context analysis and the structure of paradigms. J. Doc. 1980 , 36 , 183–196. [ Google Scholar ] [ CrossRef ]
• Chen, C.; Ibekwe-SanJuan, F.; Hou, J. The structure and dynamics of cocitation clusters: A multiple-perspective cocitation analysis. J. Am. Soc. Inf. Sci. Technol. 2010 , 61 , 1386–1409. [ Google Scholar ] [ CrossRef ]
• Egghe, L. An improvement of the h-index: The G-index. ISSI Newsl. 2006 , 2 , 8–9. [ Google Scholar ]
• Bornmann, L.; Daniel, H.D. What do we know about the h index? J. Am. Soc. Inf. Sci. Technol. 2007 , 58 , 1381–1385. [ Google Scholar ] [ CrossRef ]
• Alonso, S.; Cabrerizo, F.J.; Herrera-Viedma, E.; Herrera, F. h-Index: A review focused in its variants, computation and standardization for different scientific fields. J. Inf. 2009 , 3 , 273–289. [ Google Scholar ] [ CrossRef ]
• Chen, C. The citespace manual. Coll. Comput. Inform. 2014 , 1 , 1–84. [ Google Scholar ]
• Carollo, A.; Balagtas, J.P.M.; Neoh, M.J.Y.; Esposito, G. A scientometric approach to review the role of the medial preoptic area (MPOA) in parental behavior. Brain Sci. 2021 , 11 , 393. [ Google Scholar ] [ CrossRef ]
• Newman, M.E. Modularity and community structure in networks. Proc. Natl. Acad. Sci. USA 2006 , 103 , 8577–8582. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Rousseeuw, P.J. Silhouettes: A graphical aid to the interpretation and validation of cluster analysis. J. Comput. Appl. Math. 1987 , 20 , 53–65. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Aryadoust, V.; Ang, B.H. Exploring the frontiers of eye tracking research in language studies: A novel co-citation scientometric review. Comput. Assist. Lang. Learn. 2019 , 34 , 898–933. [ Google Scholar ] [ CrossRef ]
• Freeman, L.C. A set of measures of centrality based on betweenness. Sociometry 1977 , 40 , 35–41. [ Google Scholar ] [ CrossRef ]
• Kleinberg, J. Bursty and hierarchical structure in streams. Data Min. Knowl. Discov. 2003 , 7 , 373–397. [ Google Scholar ] [ CrossRef ]
• Gaggero, G.; Bonassi, A.; Dellantonio, S.; Pastore, L.; Aryadoust, V.; Esposito, G. A scientometric review of alexithymia: Mapping thematic and disciplinary shifts in half a century of research. Front. Psychiatry 2020 , 11 , 1405. [ Google Scholar ] [ CrossRef ]
• Carollo, A.; Lim, M.; Aryadoust, V.; Esposito, G. Interpersonal Synchrony in the Context of Caregiver-Child Interactions: A Document Co-citation Analysis. Front. Psychol. 2021 , 12 , 2977. [ Google Scholar ] [ CrossRef ]
• Lord, C.; Elsabbagh, M.; Baird, G.; Veenstra-Vanderweele, J. Autism Spectrum Disorder. Lancet 2018 , 392 , 508–520. [ Google Scholar ] [ CrossRef ]
• Grove, J.; Ripke, S.; Als, T.D.; Mattheisen, M.; Walters, R.K.; Won, H.; Pallesen, J.; Agerbo, E.; Andreassen, O.A.; Anney, R.; et al. Identification of common genetic risk variants for autism spectrum disorder. Nat. Genet. 2019 , 51 , 431–444. [ Google Scholar ] [ CrossRef ]
• Iakoucheva, L.M.; Muotri, A.R.; Sebat, J. Getting to the cores of autism. Cell 2019 , 178 , 1287–1298. [ Google Scholar ] [ CrossRef ]
• Lim, M.; Carollo, A.; Chen, S.A.; Esposito, G. Surveying 80 years of psychodrama research: A scientometric review. Front. Psychiatry 2021 , 12 , 780542. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Sharon, G.; Cruz, N.J.; Kang, D.W.; Gandal, M.J.; Wang, B.; Kim, Y.M.; Zink, E.M.; Casey, C.P.; Taylor, B.C.; Lane, C.J.; et al. Human gut microbiota from Autism Spectrum Disorder promote behavioral symptoms in mice. Cell 2019 , 177 , 1600–1618. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Ruzzo, E.K.; Pérez-Cano, L.; Jung, J.Y.; Wang, L.k.; Kashef-Haghighi, D.; Hartl, C.; Singh, C.; Xu, J.; Hoekstra, J.N.; Leventhal, O.; et al. Inherited and de novo genetic risk for autism impacts shared networks. Cell 2019 , 178 , 850–866. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Kim, Y.S.; Leventhal, B.L.; Koh, Y.J.; Fombonne, E.; Laska, E.; Lim, E.C.; Cheon, K.A.; Kim, S.J.; Kim, Y.K.; Lee, H.; et al. Prevalence of Autism Spectrum Disorders in a total population sample. Am. J. Psychiatry 2011 , 168 , 904–912. [ Google Scholar ] [ CrossRef ]
• Abraham, A.; Milham, M.P.; Di Martino, A.; Craddock, R.C.; Samaras, D.; Thirion, B.; Varoquaux, G. Deriving reproducible biomarkers from multi-site resting-state data: An Autism-based example. NeuroImage 2017 , 147 , 736–745. [ Google Scholar ] [ CrossRef ]
• Lim, E.T.; Uddin, M.; De Rubeis, S.; Chan, Y.; Kamumbu, A.S.; Zhang, X.; D’Gama, A.M.; Kim, S.N.; Hill, R.S.; Goldberg, A.P.; et al. Rates, distribution and implications of postzygotic mosaic mutations in Autism Spectrum Disorder. Nat. Neurosci. 2017 , 20 , 1217–1224. [ Google Scholar ] [ CrossRef ]
• Yang, M.; Bozdagi, O.; Scattoni, M.L.; Wöhr, M.; Roullet, F.I.; Katz, A.M.; Abrams, D.N.; Kalikhman, D.; Simon, H.; Woldeyohannes, L.; et al. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J. Neurosci. 2012 , 32 , 6525–6541. [ Google Scholar ] [ CrossRef ]
• Lee, P.H.; Anttila, V.; Won, H.; Feng, Y.C.A.; Rosenthal, J.; Zhu, Z.; Tucker-Drob, E.M.; Nivard, M.G.; Grotzinger, A.D.; Posthuma, D.; et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 2019 , 179 , 1469–1482. [ Google Scholar ] [ CrossRef ]
• Nowakowski, T.J.; Bhaduri, A.; Pollen, A.A.; Alvarado, B.; Mostajo-Radji, M.A.; Di Lullo, E.; Haeussler, M.; Sandoval-Espinosa, C.; Liu, S.J.; Velmeshev, D.; et al. Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex. Science 2017 , 358 , 1318–1323. [ Google Scholar ] [ CrossRef ]
• Velmeshev, D.; Schirmer, L.; Jung, D.; Haeussler, M.; Perez, Y.; Mayer, S.; Bhaduri, A.; Goyal, N.; Rowitch, D.H.; Kriegstein, A.R. Single-cell genomics identifies cell type–specific molecular changes in autism. Science 2019 , 364 , 685–689. [ Google Scholar ] [ CrossRef ]
• Matta, S.M.; Hill-Yardin, E.L.; Crack, P.J. The influence of neuroinflammation in Autism Spectrum Disorder. Brain Behav. Immun. 2019 , 79 , 75–90. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Estes, M.L.; McAllister, A.K. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat. Rev. Neurosci. 2015 , 16 , 469–486. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Goines, P.E.; Ashwood, P. Cytokine dysregulation in Autism Spectrum Disorders (ASD): Possible role of the environment. Neurotoxicol. Teratol. 2013 , 36 , 67–81. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Pantelis, C.; Papadimitriou, G.N.; Papiol, S.; Parkhomenko, E.; Pato, M.T.; Paunio, T.; Pejovic-Milovancevic, M.; Perkins, D.O.; Pietiläinen, O.; Pimm, J. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014 , 511 , 421–427. [ Google Scholar ]
• Yuen, R.K.; Thiruvahindrapuram, B.; Merico, D.; Walker, S.; Tammimies, K.; Hoang, N.; Chrysler, C.; Nalpathamkalam, T.; Pellecchia, G.; Liu, Y.; et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat. Med. 2015 , 21 , 185–191. [ Google Scholar ] [ CrossRef ]
• Antoine, M.W.; Langberg, T.; Schnepel, P.; Feldman, D.E. Increased excitation-inhibition ratio stabilizes synapse and circuit excitability in four autism mouse models. Neuron 2019 , 101 , 648–661. [ Google Scholar ] [ CrossRef ]
• Schafer, S.T.; Paquola, A.; Stern, S.; Gosselin, D.; Ku, M.; Pena, M.; Kuret, T.J.; Liyanage, M.; Mansour, A.A.; Jaeger, B.N.; et al. Pathological priming causes developmental gene network heterochronicity in autistic subject-derived neurons. Nat. Neurosci. 2019 , 22 , 243–255. [ Google Scholar ] [ CrossRef ]
• Stahl, E.A.; Breen, G.; Forstner, A.J.; McQuillin, A.; Ripke, S.; Trubetskoy, V.; Mattheisen, M.; Wang, Y.; Coleman, J.R.; Gaspar, H.A.; et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat. Genet. 2019 , 51 , 793–803. [ Google Scholar ] [ CrossRef ]
• Joensuu, M.; Lanoue, V.; Hotulainen, P. Dendritic spine actin cytoskeleton in Autism Spectrum Disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018 , 84 , 362–381. [ Google Scholar ] [ CrossRef ]
• Alonso-Gonzalez, A.; Rodriguez-Fontenla, C.; Carracedo, A. De novo mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and network analysis. Front. Genet. 2018 , 9 , 406. [ Google Scholar ] [ CrossRef ]
• Ayhan, F.; Konopka, G. Regulatory genes and pathways disrupted in Autism Spectrum Disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2019 , 89 , 57–64. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hui, K.; Katayama, Y.; Nakayama, K.I.; Nomura, J.; Sakurai, T. Characterizing vulnerable brain areas and circuits in mouse models of autism: Towards understanding pathogenesis and new therapeutic approaches. Neurosci. Biobehav. Rev. 2020 , 110 , 77–91. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Eyring, K.W.; Geschwind, D.H. Three decades of ASD genetics: Building a foundation for neurobiological understanding and treatment. Hum. Mol. Genet. 2021 , 30 , R236–R244. [ Google Scholar ] [ CrossRef ]
• Gandhi, T.; Lee, C.C. Neural mechanisms underlying repetitive behaviors in rodent models of Autism Spectrum Disorders. Front. Cell. Neurosci. 2021 , 14 , 592710. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Voineagu, I.; Wang, X.; Johnston, P.; Lowe, J.K.; Tian, Y.; Horvath, S.; Mill, J.; Cantor, R.M.; Blencowe, B.J.; Geschwind, D.H. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011 , 474 , 380–384. [ Google Scholar ] [ CrossRef ]
• Parikshak, N.N.; Luo, R.; Zhang, A.; Won, H.; Lowe, J.K.; Chandran, V.; Horvath, S.; Geschwind, D.H. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 2013 , 155 , 1008–1021. [ Google Scholar ] [ CrossRef ]
• De Rubeis, S.; He, X.; Goldberg, A.P.; Poultney, C.S.; Samocha, K.; Ercument Cicek, A.; Kou, Y.; Liu, L.; Fromer, M.; Walker, S.; et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014 , 515 , 209–215. [ Google Scholar ] [ CrossRef ]
• Guang, S.; Pang, N.; Deng, X.; Yang, L.; He, F.; Wu, L.; Chen, C.; Yin, F.; Peng, J. Synaptopathology involved in Autism Spectrum Disorder. Front. Cell. Neurosci. 2018 , 12 , 470. [ Google Scholar ] [ CrossRef ]
• Garcia-Forn, M.; Boitnott, A.; Akpinar, Z.; De Rubeis, S. Linking autism risk genes to disruption of cortical development. Cells 2020 , 9 , 2500. [ Google Scholar ] [ CrossRef ]
• Diaz-Caneja, C.M.; State, M.; Hagerman, R.; Jacquemont, S.; Marín, O.; Bagni, C.; Umbricht, D.; Simonoff, E.; de Andrés-Trelles, F.; Kaale, A.; et al. A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. Eur. Neuropsychopharmacol. 2021 , 48 , 49–88. [ Google Scholar ] [ CrossRef ]
• DiCarlo, G.E.; Wallace, M.T. Modeling dopamine dysfunction in Autism Spectrum Disorder: From invertebrates to vertebrates. Neurosci. Biobehav. Rev. 2021 , 133 , 104494. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Zheng, Y.; Verhoeff, T.A.; Perez Pardo, P.; Garssen, J.; Kraneveld, A.D. The gut–brain axis in Autism Spectrum Disorder: A focus on the metalloproteases ADAM10 and ADAM17. Int. J. Mol. Sci. 2020 , 22 , 118. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Cryan, J.F.; O’Riordan, K.J.; Cowan, C.S.; Sandhu, K.V.; Bastiaanssen, T.F.; Boehme, M.; Codagnone, M.G.; Cussotto, S.; Fulling, C.; Golubeva, A.V.; et al. The microbiota-gut–brain axis. Physiol. Rev. 2019 , 99 , 1877–2013. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Fattorusso, A.; Di Genova, L.; Dell’Isola, G.B.; Mencaroni, E.; Esposito, S. Autism Spectrum Disorders and the gut microbiota. Nutrients 2019 , 11 , 521. [ Google Scholar ] [ CrossRef ]
• Srikantha, P.; Mohajeri, M.H. The possible role of the microbiota-gut–brain-axis in autism spectrum disorder. Int. J. Mol. Sci. 2019 , 20 , 2115. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hooks, K.B.; Konsman, J.P.; O’Malley, M.A. Microbiota-gut–brain research: A critical analysis. Behav. Brain Sci. 2019 , 42 , e60. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Azhari, A.; Azizan, F.; Esposito, G. Beyond a gut feeling: How the immune system impacts the effect of gut microbiota in neurodevelopment. Behav. Brain Sci. 2019 , 42 . [ Google Scholar ] [ CrossRef ]
• van Sadelhoff, J.H.; Perez Pardo, P.; Wu, J.; Garssen, J.; Van Bergenhenegouwen, J.; Hogenkamp, A.; Hartog, A.; Kraneveld, A.D. The gut-immune-brain axis in Autism Spectrum Disorders; a focus on amino acids. Front. Endocrinol. 2019 , 10 , 247. [ Google Scholar ] [ CrossRef ]
• Tomova, A.; Husarova, V.; Lakatosova, S.; Bakos, J.; Vlkova, B.; Babinska, K.; Ostatnikova, D. Gastrointestinal microbiota in children with autism in Slovakia. Physiol. Behav. 2015 , 138 , 179–187. [ Google Scholar ] [ CrossRef ]
• Liu, Z.; Mao, X.; Dan, Z.; Pei, Y.; Xu, R.; Guo, M.; Liu, K.; Zhang, F.; Chen, J.; Su, C.; et al. Gene variations in Autism Spectrum Disorder are associated with alternation of gut microbiota, metabolites and cytokines. Gut Microbes 2021 , 13 , 1854967. [ Google Scholar ] [ CrossRef ]
• Taniya, M.A.; Chung, H.J.; Al Mamun, A.; Alam, S.; Aziz, M.; Emon, N.U.; Islam, M.; Podder, B.R.; Ara Mimi, A.; Aktar Suchi, S.; et al. Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation. Front. Cell. Infect. Microbiol. 2022 , 12 , 915701. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Patel, J.; Lukkes, J.L.; Shekhar, A. Overview of genetic models of Autism Spectrum Disorders. Prog. Brain Res. 2018 , 241 , 1–36. [ Google Scholar ] [ PubMed ]
• Yang, G.; Shcheglovitov, A. Probing disrupted neurodevelopment in autism using human stem cell-derived neurons and organoids: An outlook into future diagnostics and drug development. Dev. Dyn. 2020 , 249 , 6–33. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Panisi, C.; Guerini, F.R.; Abruzzo, P.M.; Balzola, F.; Biava, P.M.; Bolotta, A.; Brunero, M.; Burgio, E.; Chiara, A.; Clerici, M.; et al. Autism Spectrum Disorder from the womb to adulthood: Suggestions for a paradigm shift. J. Pers. Med. 2021 , 11 , 70. [ Google Scholar ] [ CrossRef ]
• Liu, Q.; Chen, M.X.; Sun, L.; Wallis, C.U.; Zhou, J.S.; Ao, L.J.; Li, Q.; Sham, P.C. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World J. Stem Cells 2019 , 11 , 55. [ Google Scholar ] [ CrossRef ]
• Lombardo, M.V.; Moon, H.M.; Su, J.; Palmer, T.D.; Courchesne, E.; Pramparo, T. Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. Mol. Psychiatry 2018 , 23 , 1001–1013. [ Google Scholar ] [ CrossRef ]
• Möhrle, D.; Fernández, M.; Peñagarikano, O.; Frick, A.; Allman, B.; Schmid, S. What we can learn from a genetic rodent model about autism. Neurosci. Biobehav. Rev. 2020 , 109 , 29–53. [ Google Scholar ] [ CrossRef ]
• Verma, V.; Paul, A.; Amrapali Vishwanath, A.; Vaidya, B.; Clement, J.P. Understanding intellectual disability and Autism Spectrum Disorders from common mouse models: Synapses to behaviour. Open Biol. 2019 , 9 , 180265. [ Google Scholar ] [ CrossRef ]
• Nakai, N.; Takumi, T.; Nakai, J.; Sato, M. Common defects of spine dynamics and circuit function in neurodevelopmental disorders: A systematic review of findings from in vivo optical imaging of mouse models. Front. Neurosci. 2018 , 12 , 412. [ Google Scholar ] [ CrossRef ]
• Sungur, A.Ö.; Schwarting, R.K.; Woehr, M. Behavioral phenotypes and neurobiological mechanisms in the Shank1 mouse model for Autism Spectrum Disorder: A translational perspective. Behav. Brain Res. 2018 , 352 , 46–61. [ Google Scholar ] [ CrossRef ]
• Wang, X.; Kery, R.; Xiong, Q. Synaptopathology in Autism Spectrum Disorders: Complex effects of synaptic genes on neural circuits. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018 , 84 , 398–415. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Soler, J.; Fañanás, L.; Parellada, M.; Krebs, M.O.; Rouleau, G.A.; Fatjó-Vilas, M. Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: A systematic review. J. Psychiatry Neurosci. 2018 , 43 , 223–244. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Consorthium, T.D.B.F.X.; Bakker, C.E.; Verheij, C.; Willemsen, R.; van der Helm, R.; Oerlemans, F.; Vermey, M.; Bygrave, A.; Hoogeveen, A.; Oostra, B.A.; et al. Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 1994 , 78 , 23–33. [ Google Scholar ]
• Bagni, C.; Zukin, R.S. A synaptic perspective of fragile X syndrome and autism spectrum disorders. Neuron 2019 , 101 , 1070–1088. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Kaufmann, W.E.; Kidd, S.A.; Andrews, H.F.; Budimirovic, D.B.; Esler, A.; Haas-Givler, B.; Stackhouse, T.; Riley, C.; Peacock, G.; Sherman, S.L.; et al. Autism Spectrum Disorder in fragile X syndrome: Cooccurring conditions and current treatment. Pediatrics 2017 , 139 , S194–S206. [ Google Scholar ] [ CrossRef ]
• Clifford, S.; Dissanayake, C.; Bui, Q.M.; Huggins, R.; Taylor, A.K.; Loesch, D.Z. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J. Autism Dev. Disord. 2007 , 37 , 738–747. [ Google Scholar ] [ CrossRef ]
• Verkerk, A.J.; Pieretti, M.; Sutcliffe, J.S.; Fu, Y.H.; Kuhl, D.P.; Pizzuti, A.; Reiner, O.; Richards, S.; Victoria, M.F.; Zhang, F.; et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991 , 65 , 905–914. [ Google Scholar ] [ CrossRef ]
• Gibson, J.R.; Bartley, A.F.; Hays, S.A.; Huber, K.M. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J. Neurophysiol. 2008 , 100 , 2615–2626. [ Google Scholar ] [ CrossRef ]
• Yoo, T.; Cho, H.; Park, H.; Lee, J.; Kim, E. Shank3 exons 14–16 deletion in glutamatergic neurons leads to social and repetitive behavioral deficits associated with increased cortical layer 2/3 neuronal excitability. Front. Cell. Neurosci. 2019 , 13 , 458. [ Google Scholar ] [ CrossRef ]
• Mossa, A.; Giona, F.; Pagano, J.; Sala, C.; Verpelli, C. SHANK genes in autism: Defining therapeutic targets. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018 , 84 , 416–423. [ Google Scholar ] [ CrossRef ]
• Yoo, T.; Cho, H.; Lee, J.; Park, H.; Yoo, Y.E.; Yang, E.; Kim, J.Y.; Kim, H.; Kim, E. GABA neuronal deletion of Shank3 exons 14–16 in mice suppresses striatal excitatory synaptic input and induces social and locomotor abnormalities. Front. Cell. Neurosci. 2018 , 12 , 341. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Monteiro, P.; Feng, G. SHANK proteins: Roles at the synapse and in Autism Spectrum Disorder. Nat. Rev. Neurosci. 2017 , 18 , 147–157. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Chaudry, S.; Vasudevan, N. mTOR-dependent spine dynamics in autism. Front. Mol. Neurosci. 2022 , 15 , 877609. [ Google Scholar ] [ CrossRef ]
• Ali Rodriguez, R.; Joya, C.; Hines, R.M. Common ribs of inhibitory synaptic dysfunction in the umbrella of neurodevelopmental disorders. Front. Mol. Neurosci. 2018 , 11 , 132. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• St. Clair, D.; Johnstone, M. Using mouse transgenic and human stem cell technologies to model genetic mutations associated with schizophrenia and autism. Philos. Trans. R. Soc. Biol. Sci. 2018 , 373 , 20170037. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Lord, C.; Brugha, T.S.; Charman, T.; Cusack, J.; Dumas, G.; Frazier, T.; Jones, E.J.; Jones, R.M.; Pickles, A.; State, M.W.; et al. Autism Spectrum Disorder. Nat. Rev. Dis. Prim. 2020 , 6 , 1–23. [ Google Scholar ] [ CrossRef ]
• Vallortigara, G. Born Knowing: Imprinting and the Origins of Knowledge ; MIT Press: Cambridge, MA, USA, 2021. [ Google Scholar ]
• Tartaglione, A.M.; Schiavi, S.; Calamandrei, G.; Trezza, V. Prenatal valproate in rodents as a tool to understand the neural underpinnings of social dysfunctions in Autism Spectrum Disorder. Neuropharmacology 2019 , 159 , 107477. [ Google Scholar ] [ CrossRef ]
• Fink, J.J.; Levine, E.S. Uncovering true cellular phenotypes: Using induced pluripotent stem cell-derived neurons to study early insults in neurodevelopmental disorders. Front. Neurol. 2018 , 9 , 237. [ Google Scholar ] [ CrossRef ]
• Maussion, G.; Rocha, C.; Bernard, G.; Beitel, L.K.; Durcan, T.M. Patient-derived stem cells, another in vitro model, or the missing link toward novel therapies for Autism Spectrum Disorders? Front. Pediatr. 2019 , 7 , 225. [ Google Scholar ] [ CrossRef ]
• Sato, A.; Kotajima-Murakami, H.; Tanaka, M.; Katoh, Y.; Ikeda, K. Influence of prenatal drug exposure, maternal inflammation, and parental aging on the development of Autism Spectrum Disorder. Front. Psychiatry 2022 , 13 , 821455. [ Google Scholar ] [ CrossRef ]
• Ilieva, M.; Svenningsen, Å.F.; Thorsen, M.; Michel, T.M. Psychiatry in a dish: Stem cells and brain organoids modeling autism spectrum disorders. Biol. Psychiatry 2018 , 83 , 558–568. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Chan, W.K.; Griffiths, R.; Price, D.J.; Mason, J.O. Cerebral organoids as tools to identify the developmental roots of autism. Mol. Autism 2020 , 11 , 1–14. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Baldassari, S.; Musante, I.; Iacomino, M.; Zara, F.; Salpietro, V.; Scudieri, P. Brain organoids as model systems for genetic neurodevelopmental disorders. Front. Cell Dev. Biol. 2020 , 8 , 590119. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Shou, Y.; Liang, F.; Xu, S.; Li, X. The application of brain organoids: From neuronal development to neurological diseases. Front. Cell Dev. Biol. 2020 , 8 , 579659. [ Google Scholar ] [ CrossRef ]
• de Jong, J.O.; Llapashtica, C.; Genestine, M.; Strauss, K.; Provenzano, F.; Sun, Y.; Zhu, H.; Cortese, G.P.; Brundu, F.; Brigatti, K.W.; et al. Cortical overgrowth in a preclinical forebrain organoid model of CNTNAP2-associated Autism Spectrum Disorder. Nat. Commun. 2021 , 12 , 1–14. [ Google Scholar ] [ CrossRef ]
• Sun, N.; Meng, X.; Liu, Y.; Song, D.; Jiang, C.; Cai, J. Applications of brain organoids in neurodevelopment and neurological diseases. J. Biomed. Sci. 2021 , 28 , 1–16. [ Google Scholar ] [ CrossRef ]
• Silverman, J.L.; Thurm, A.; Ethridge, S.B.; Soller, M.M.; Petkova, S.P.; Abel, T.; Bauman, M.D.; Brodkin, E.S.; Harony-Nicolas, H.; Wöhr, M.; et al. Reconsidering animal models used to study Autism Spectrum Disorder: Current state and optimizing future. Genes Brain Behav. 2022 , 21 , e12803. [ Google Scholar ] [ CrossRef ]
• Tordjman, S.; Drapier, D.; Bonnot, O.; Graignic, R.; Fortes, S.; Cohen, D.; Millet, B.; Laurent, C.; Roubertoux, P.L. Animal models relevant to schizophrenia and autism: Validity and limitations. Behav. Genet. 2007 , 37 , 61–78. [ Google Scholar ] [ CrossRef ]
• Siniscalco, D.; Sapone, A.; Cirillo, A.; Giordano, C.; Maione, S.; Antonucci, N. Autism Spectrum Disorders: Is mesenchymal stem cell personalized therapy the future? J. Biomed. Biotechnol. 2012 , 2012 , 480289. [ Google Scholar ] [ CrossRef ]
• Filice, F.; Janickova, L.; Henzi, T.; Bilella, A.; Schwaller, B. The parvalbumin hypothesis of Autism Spectrum Disorder. Front. Cell. Neurosci. 2020 , 14 , 577525. [ Google Scholar ] [ CrossRef ]
• Napolitano, A.; Schiavi, S.; La Rosa, P.; Rossi-Espagnet, M.C.; Petrillo, S.; Bottino, F.; Tagliente, E.; Longo, D.; Lupi, E.; Casula, L.; et al. Sex Differences in Autism Spectrum Disorder: Diagnostic, Neurobiological, and Behavioral Features. Front. Psychiatry 2022 , 13 , 889636. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Courchesne, E.; Gazestani, V.H.; Lewis, N.E. Prenatal origins of ASD: The when, what, and how of ASD development. Trends Neurosci. 2020 , 43 , 326–342. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hoffmann, A.; Ziller, M.; Spengler, D. Childhood-onset schizophrenia: Insights from induced pluripotent stem cells. Int. J. Mol. Sci. 2018 , 19 , 3829. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hong, S.J.; Vogelstein, J.T.; Gozzi, A.; Bernhardt, B.C.; Yeo, B.T.; Milham, M.P.; Di Martino, A. Toward neurosubtypes in autism. Biol. Psychiatry 2020 , 88 , 111–128. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Niu, W.; Parent, J.M. Modeling genetic epilepsies in a dish. Dev. Dyn. 2020 , 249 , 56–75. [ Google Scholar ] [ CrossRef ]
• Fetit, R.; Hillary, R.F.; Price, D.J.; Lawrie, S.M. The neuropathology of autism: A systematic review of post-mortem studies of autism and related disorders. Neurosci. Biobehav. Rev. 2021 , 129 , 35–62. [ Google Scholar ] [ CrossRef ]
• Griesi-Oliveira, K.; Fogo, M.; Pinto, B.; Alves, A.; Suzuki, A.; Morales, A.; Ezquina, S.; Sosa, O.; Sutton, G.; Sunaga-Franze, D.; et al. Transcriptome of iPSC-derived neuronal cells reveals a module of co-expressed genes consistently associated with Autism Spectrum Disorder. Mol. Psychiatry 2021 , 26 , 1589–1605. [ Google Scholar ] [ CrossRef ]
• Al-Dewik, N.; Al-Jurf, R.; Styles, M.; Tahtamouni, S.; Alsharshani, D.; Alsharshani, M.; Ahmad, A.I.; Khattab, A.; Al Rifai, H.; Walid Qoronfleh, M. Overview and introduction to Autism Spectrum Disorder (ASD). In Personalized Food Intervention and Therapy for Autism Spectrum Disorder Management ; Springer: Cham, Switzerland, 2020; pp. 3–42. [ Google Scholar ]
• Breen, M.S.; Browne, A.; Hoffman, G.E.; Stathopoulos, S.; Brennand, K.; Buxbaum, J.D.; Drapeau, E. Transcriptional signatures of participant-derived neural progenitor cells and neurons implicate altered Wnt signaling in Phelan-McDermid syndrome and autism. Mol. Autism 2020 , 11 , 53. [ Google Scholar ] [ CrossRef ]
• Seabra, C.M.; Aneichyk, T.; Erdin, S.; Tai, D.J.; De Esch, C.E.; Razaz, P.; An, Y.; Manavalan, P.; Ragavendran, A.; Stortchevoi, A.; et al. Transcriptional consequences of MBD5 disruption in mouse brain and CRISPR-derived neurons. Mol. Autism 2020 , 11 , 45. [ Google Scholar ] [ CrossRef ]
• Brusco, A.; Ferrero, G.B. Genomic Architecture of ASD. In Psychopathology in Adolescents and Adults with Autism Spectrum Disorders ; Springer: Cham, Switzerland, 2019; pp. 23–34. [ Google Scholar ]
• Rogozin, I.B.; Gertz, E.M.; Baranov, P.V.; Poliakov, E.; Schaffer, A.A. Genome-wide changes in protein translation efficiency are associated with autism. Genome Biol. Evol. 2018 , 10 , 1902–1919. [ Google Scholar ] [ CrossRef ]
• Chen, T.; Froehlich, T.; Li, T.; Lu, L. Big data approaches to develop a comprehensive and accurate tool aimed at improving Autism Spectrum Disorder diagnosis and subtype stratification. Libr. Tech. 2020 , 38 , 819–833. [ Google Scholar ] [ CrossRef ]
• Nehme, R.; Barrett, L.E. Using human pluripotent stem cell models to study autism in the era of big data. Mol. Autism 2020 , 11 , 21. [ Google Scholar ] [ CrossRef ]
• Liu, H.; Barnes, J.; Pedrosa, E.; Herman, N.S.; Salas, F.; Wang, P.; Zheng, D.; Lachman, H.M. Transcriptome analysis of neural progenitor cells derived from Lowe syndrome induced pluripotent stem cells: Identification of candidate genes for the neurodevelopmental and eye manifestations. J. Neurodev. Disord. 2020 , 12 , 14. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Cantor, R.M.; Lowe, J.K. Genome-wide association studies and neurodevelopment: Autism spectrum disorders and related traits. In Factors Affecting Neurodevelopment ; Elsevier: Cham, Switzerland, 2021; pp. 27–37. [ Google Scholar ]
• Culotta, L.; Penzes, P. Exploring the mechanisms underlying excitation/inhibition imbalance in human iPSC-derived models of ASD. Mol. Autism 2020 , 11 , 32. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Gordon, A.; Geschwind, D.H. Human in vitro models for understanding mechanisms of autism spectrum disorder. Mol. Autism 2020 , 11 , 26. [ Google Scholar ] [ CrossRef ]
• Prem, S.; Millonig, J.H.; DiCicco-Bloom, E. Dysregulation of neurite outgrowth and cell migration in autism and other neurodevelopmental disorders. In Neurodevelopmental Disorders ; Springer: Cham, Switzerland, 2020; pp. 109–153. [ Google Scholar ]
• Muhle, R.A.; Reed, H.E.; Stratigos, K.A.; Veenstra-VanderWeele, J. The emerging clinical neuroscience of Autism Spectrum Disorder: A review. JAMA Psychiatry 2018 , 75 , 514–523. [ Google Scholar ] [ CrossRef ]
• Grabrucker, A. Biometals in Autism Spectrum Disorders ; Academic Press: Cambridge, MA, USA, 2020. [ Google Scholar ]
• Saxena, R.; Babadi, M.; Namvarhaghighi, H.; Roullet, F.I. Role of environmental factors and epigenetics in autism spectrum disorders. Prog. Mol. Biol. Transl. Sci. 2020 , 173 , 35–60. [ Google Scholar ]
• Scuderi, C.; Verkhratsky, A. The role of neuroglia in Autism Spectrum Disorders. Prog. Mol. Biol. Transl. Sci. 2020 , 173 , 301–330. [ Google Scholar ]
• Zhang, X.; Abdellaoui, A.; Rucker, J.; de Jong, S.; Potash, J.B.; Weissman, M.M.; Shi, J.; Knowles, J.A.; Pato, C.; Pato, M.; et al. Genome-wide burden of rare short deletions is enriched in major depressive disorder in four cohorts. Biol. Psychiatry 2019 , 85 , 1065–1073. [ Google Scholar ] [ CrossRef ]
• Campbell, P.D.; Granato, M. Zebrafish as a tool to study schizophrenia-associated copy number variants. Dis. Model. Mech. 2020 , 13 , dmm043877. [ Google Scholar ] [ CrossRef ]
• Nehme, R.; Pietiläinen, O.; Artomov, M.; Tegtmeyer, M.; Valakh, V.; Lehtonen, L.; Bell, C.; Singh, T.; Trehan, A.; Sherwood, J.; et al. The 22q11. 2 region regulates presynaptic gene-products linked to schizophrenia. Nat. Commun. 2022 , 13 , 3690. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Degenhardt, F. Update on the genetic architecture of schizophrenia. Med. Genet. 2020 , 32 , 19–24. [ Google Scholar ] [ CrossRef ]
• Strom, N.I.; Grove, J.; Meier, S.M.; Bækvad-Hansen, M.; Nissen, J.B.; Als, T.D.; Halvorsen, M.; Nordentoft, M.; Mortensen, P.B.; Hougaard, D.M.; et al. Polygenic heterogeneity across obsessive-compulsive disorder subgroups defined by a comorbid diagnosis. Front. Genet. 2021 , 12 , 711624. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Bryois, J.; Skene, N.G.; Hansen, T.F.; Kogelman, L.J.; Watson, H.J.; Liu, Z.; Brueggeman, L.; Breen, G.; Bulik, C.M.; Arenas, E.; et al. Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson’s disease. Nat. Genet. 2020 , 52 , 482–493. [ Google Scholar ] [ CrossRef ]
• Yang, Z.; Wu, H.; Lee, P.H.; Tsetsos, F.; Davis, L.K.; Yu, D.; Lee, S.H.; Dalsgaard, S.; Haavik, J.; Barta, C.; et al. Investigating shared genetic basis across tourette syndrome and comorbid neurodevelopmental disorders along the impulsivity-compulsivity spectrum. Biol. Psychiatry 2021 , 90 , 317–327. [ Google Scholar ] [ CrossRef ]
• Warrier, V.; Baron-Cohen, S. Childhood trauma, life-time self-harm, and suicidal behaviour and ideation are associated with polygenic scores for autism. Mol. Psychiatry 2021 , 26 , 1670–1684. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Bralten, J.; Mota, N.R.; Klemann, C.J.; De Witte, W.; Laing, E.; Collier, D.A.; de Kluiver, H.; Bauduin, S.E.; Arango, C.; Ayuso-Mateos, J.L.; et al. Genetic underpinnings of sociability in the general population. Neuropsychopharmacology 2021 , 46 , 1627–1634. [ Google Scholar ] [ CrossRef ]
• Park, C.Y.; Zhou, J.; Wong, A.K.; Chen, K.M.; Theesfeld, C.L.; Darnell, R.B.; Troyanskaya, O.G. Genome-wide landscape of RNA-binding protein target site dysregulation reveals a major impact on psychiatric disorder risk. Nat. Genet. 2021 , 53 , 166–173. [ Google Scholar ] [ CrossRef ]
• Jiang, C.C.; Lin, L.S.; Long, S.; Ke, X.Y.; Fukunaga, K.; Lu, Y.M.; Han, F. Signalling pathways in Autism Spectrum Disorder: Mechanisms and therapeutic implications. Signal Transduct. Target. Ther. 2022 , 7 , 1–36. [ Google Scholar ] [ CrossRef ]
• Urresti, J.; Zhang, P.; Moran-Losada, P.; Yu, N.K.; Negraes, P.D.; Trujillo, C.A.; Antaki, D.; Amar, M.; Chau, K.; Pramod, A.B.; et al. Cortical organoids model early brain development disrupted by 16p11. 2 copy number variants in autism. Mol. Psychiatry 2021 , 26 , 7560–7580. [ Google Scholar ] [ CrossRef ]
• Walker, R.L.; Ramaswami, G.; Hartl, C.; Mancuso, N.; Gandal, M.J.; De La Torre-Ubieta, L.; Pasaniuc, B.; Stein, J.L.; Geschwind, D.H. Genetic control of expression and splicing in developing human brain informs disease mechanisms. Cell 2019 , 179 , 750–771. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Willsey, H.R.; Willsey, A.J.; Wang, B.; State, M.W. Genomics, convergent neuroscience and progress in understanding Autism Spectrum Disorder. Nat. Rev. Neurosci. 2022 , 23 , 323–341. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Sullivan, P.F.; Geschwind, D.H. Defining the genetic, genomic, cellular, and diagnostic architectures of psychiatric disorders. Cell 2019 , 177 , 162–183. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Rees, E.; Owen, M.J. Translating insights from neuropsychiatric genetics and genomics for precision psychiatry. Genome Med. 2020 , 12 , 1–16. [ Google Scholar ] [ CrossRef ]
• Mullins, N.; Forstner, A.J.; O’Connell, K.S.; Coombes, B.; Coleman, J.R.; Qiao, Z.; Als, T.D.; Bigdeli, T.B.; Børte, S.; Bryois, J.; et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat. Genet. 2021 , 53 , 817–829. [ Google Scholar ] [ CrossRef ]
• Rujeedawa, T.; Zaman, S.H. The Diagnosis and Management of Autism Spectrum Disorder (ASD) in Adult Females in the Presence or Absence of an Intellectual Disability. Int. J. Environ. Res. Public Health 2022 , 19 , 1315. [ Google Scholar ] [ CrossRef ]
• Ruigrok, A.N.; Lai, M.C. Sex/gender differences in neurology and psychiatry: Autism. Handb. Clin. Neurol. 2020 , 175 , 283–297. [ Google Scholar ]
• Lombardo, M.V.; Auyeung, B.; Pramparo, T.; Quartier, A.; Courraud, J.; Holt, R.J.; Waldman, J.; Ruigrok, A.N.; Mooney, N.; Bethlehem, R.A.; et al. Sex-specific impact of prenatal androgens on social brain default mode subsystems. Mol. Psychiatry 2020 , 25 , 2175–2188. [ Google Scholar ] [ CrossRef ]
• Nowak, S.; Jacquemont, S. The effects of sex on prevalence and mechanisms underlying neurodevelopmental disorders. In Handbook of Clinical Neurology ; Elsevier: Cham, Switzerland, 2020; Volume 173, pp. 327–339. [ Google Scholar ]
• Kallitsounaki, A.; Williams, D.M. Autism Spectrum Disorder and Gender Dysphoria/Incongruence. A systematic Literature Review and Meta-Analysis. J. Autism Dev. Disord. 2022 , 1–15. [ Google Scholar ] [ CrossRef ]
• Loomes, R.; Hull, L.; Mandy, W.P.L. What is the male-to-female ratio in Autism Spectrum Disorder? A systematic review and meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry 2017 , 56 , 466–474. [ Google Scholar ] [ CrossRef ]
• Lai, M.C.; Anagnostou, E.; Wiznitzer, M.; Allison, C.; Baron-Cohen, S. Evidence-based support for autistic people across the lifespan: Maximising potential, minimising barriers, and optimising the person–environment fit. Lancet Neurol. 2020 , 19 , 434–451. [ Google Scholar ] [ CrossRef ]
• Müller, R.A.; Fishman, I. Brain connectivity and neuroimaging of social networks in autism. Trends Cogn. Sci. 2018 , 22 , 1103–1116. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Wilson, H.A.; Creighton, C.; Scharfman, H.; Choleris, E.; MacLusky, N.J. Endocrine insights into the pathophysiology of autism spectrum disorder. Neuroscientist 2021 , 27 , 650–667. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Howes, O.D.; Rogdaki, M.; Findon, J.L.; Wichers, R.H.; Charman, T.; King, B.H.; Loth, E.; McAlonan, G.M.; McCracken, J.T.; Parr, J.R.; et al. Autism Spectrum Disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J. Psychopharmacol. 2018 , 32 , 3–29. [ Google Scholar ] [ CrossRef ]
• Yuen, T.; Carter, M.T.; Szatmari, P.; Ungar, W.J. Cost-effectiveness of genome and exome sequencing in children diagnosed with Autism Spectrum Disorder. Appl. Health Econ. Health Policy 2018 , 16 , 481–493. [ Google Scholar ] [ CrossRef ]
• Jønch, A.E.; Douard, E.; Moreau, C.; Van Dijck, A.; Passeggeri, M.; Kooy, F.; Puechberty, J.; Campbell, C.; Sanlaville, D.; Lefroy, H.; et al. Estimating the effect size of the 15Q11. 2 BP1–BP2 deletion and its contribution to neurodevelopmental symptoms: Recommendations for practice. J. Med. Genet. 2019 , 56 , 701–710. [ Google Scholar ] [ CrossRef ]
• Rosenberg, L.E.; Rosenberg, D.D. Human Genes and Genomes: Science, Health, Society ; Academic Press: Cambridge, MA, USA, 2012; Volume 2. [ Google Scholar ]
• Shishido, E.; Aleksic, B.; Ozaki, N. Copy-number variation in the pathogenesis of autism spectrum disorder. Psychiatry Clin. Neurosci. 2014 , 68 , 85–95. [ Google Scholar ] [ CrossRef ]
• Egolf, L.E.; Vaksman, Z.; Lopez, G.; Rokita, J.L.; Modi, A.; Basta, P.V.; Hakonarson, H.; Olshan, A.F.; Diskin, S.J. Germline 16p11. 2 microdeletion predisposes to neuroblastoma. Am. J. Hum. Genet. 2019 , 105 , 658–668. [ Google Scholar ] [ CrossRef ]
• Lengyel, A.; Pinti, É.; Pikó, H.; Jávorszky, E.; David, D.; Tihanyi, M.; Gönczi, É.; Kiss, E.; Tóth, Z.; Tory, K.; et al. Clinical and genetic findings in Hungarian pediatric patients carrying chromosome 16p copy number variants and a review of the literature. Eur. J. Med. Genet. 2020 , 63 , 104027. [ Google Scholar ] [ CrossRef ]
• Bristow, G.C.; Thomson, D.M.; Openshaw, R.L.; Mitchell, E.J.; Pratt, J.A.; Dawson, N.; Morris, B.J. 16p11 Duplication disrupts hippocampal-orbitofrontal-amygdala connectivity, revealing a neural circuit endophenotype for schizophrenia. Cell Rep. 2020 , 31 , 107536. [ Google Scholar ] [ CrossRef ]
• Pucilowska, J.; Vithayathil, J.; Pagani, M.; Kelly, C.; Karlo, J.C.; Robol, C.; Morella, I.; Gozzi, A.; Brambilla, R.; Landreth, G.E. Pharmacological inhibition of ERK signaling rescues pathophysiology and behavioral phenotype associated with 16p11. 2 chromosomal deletion in mice. J. Neurosci. 2018 , 38 , 6640–6652. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Niarchou, M.; Chawner, S.J.; Doherty, J.L.; Maillard, A.M.; Jacquemont, S.; Chung, W.K.; Green-Snyder, L.; Bernier, R.A.; Goin-Kochel, R.P.; Hanson, E.; et al. Psychiatric disorders in children with 16p11. 2 deletion and duplication. Transl. Psychiatry 2019 , 9 , 1–8. [ Google Scholar ]
• Ip, J.P.; Nagakura, I.; Petravicz, J.; Li, K.; Wiemer, E.A.; Sur, M. Major vault protein, a candidate gene in 16p11. 2 microdeletion syndrome, is required for the homeostatic regulation of visual cortical plasticity. J. Neurosci. 2018 , 38 , 3890–3900. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Poot, M. Syndromes hidden within the 16p11. 2 deletion region. Mol. Syndromol. 2018 , 9 , 171–174. [ Google Scholar ] [ CrossRef ]
• Rein, B.; Yan, Z. 16p11. 2 copy number variations and neurodevelopmental disorders. Trends Neurosci. 2020 , 43 , 886–901. [ Google Scholar ] [ CrossRef ]
• Weiss, L.A.; Shen, Y.; Korn, J.M.; Arking, D.E.; Miller, D.T.; Fossdal, R.; Saemundsen, E.; Stefansson, H.; Ferreira, M.A.; Green, T.; et al. Association between microdeletion and microduplication at 16p11. 2 and autism. N. Engl. J. Med. 2008 , 358 , 667–675. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Marshall, C.R.; Howrigan, D.P.; Merico, D.; Thiruvahindrapuram, B.; Wu, W.; Greer, D.S.; Antaki, D.; Shetty, A.; Holmans, P.A.; Pinto, D.; et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat. Genet. 2017 , 49 , 27–35. [ Google Scholar ] [ CrossRef ]
• Stefansson, H.; Meyer-Lindenberg, A.; Steinberg, S.; Magnusdottir, B.; Morgen, K.; Arnarsdottir, S.; Bjornsdottir, G.; Walters, G.B.; Jonsdottir, G.A.; Doyle, O.M.; et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature 2014 , 505 , 361–366. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Deshpande, A.; Weiss, L.A. Recurrent reciprocal copy number variants: Roles and rules in neurodevelopmental disorders. Dev. Neurobiol. 2018 , 78 , 519–530. [ Google Scholar ] [ CrossRef ]
• Takumi, T.; Tamada, K. CNV biology in neurodevelopmental disorders. Curr. Opin. Neurobiol. 2018 , 48 , 183–192. [ Google Scholar ] [ CrossRef ]
• Kushima, I.; Aleksic, B.; Nakatochi, M.; Shimamura, T.; Okada, T.; Uno, Y.; Morikawa, M.; Ishizuka, K.; Shiino, T.; Kimura, H.; et al. Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights. Cell Rep. 2018 , 24 , 2838–2856. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Zwaigenbaum, L.; Duku, E.; Fombonne, E.; Szatmari, P.; Smith, I.M.; Bryson, S.E.; Mirenda, P.; Vaillancourt, T.; Volden, J.; Georgiades, S.; et al. Developmental functioning and symptom severity influence age of diagnosis in Canadian preschool children with autism. Paediatr. Child Health 2019 , 24 , e57–e65. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Atherton, G.; Edisbury, E.; Piovesan, A.; Cross, L. Autism through the ages: A mixed methods approach to understanding how age and age of diagnosis affect quality of life. J. Autism Dev. Disord. 2022 , 52 , 3639–3654. [ Google Scholar ] [ CrossRef ]
• Pender, R.; Fearon, P.; Heron, J.; Mandy, W. The longitudinal heterogeneity of autistic traits: A systematic review. Res. Autism Spectr. Disord. 2020 , 79 , 101671. [ Google Scholar ] [ CrossRef ]
• Kirst, S.; Diehm, R.; Bögl, K.; Wilde-Etzold, S.; Bach, C.; Noterdaeme, M.; Poustka, L.; Ziegler, M.; Dziobek, I. Fostering socio-emotional competencies in children on the autism spectrum using a parent-assisted serious game: A multicenter randomized controlled trial. Behav. Res. Ther. 2022 , 152 , 104068. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Rozenblatt-Perkal, Y.; Zaidman-Zait, A. Mother–child interaction in families of children with autism: Interpersonal dyadic processes. Res. Autism Spectr. Disord. 2020 , 79 , 101689. [ Google Scholar ] [ CrossRef ]
• Reinhartsen, D.; Tapia, A.; Watson, L.; Crais, E.; Bradley, C.; Fairchild, J.; Herring, A.; Daniels, J. Expressive dominant versus receptive dominant language patterns in young children: Findings from the study to explore early development. J. Autism Dev. Disord. 2019 , 49 , 2447–2460. [ Google Scholar ] [ CrossRef ]
• Belcher, H.L.; Morein-Zamir, S.; Stagg, S.D.; Ford, R.M. Shining a Light on a Hidden Population: Social Functioning and Mental Health in Women Reporting Autistic Traits But Lacking Diagnosis. J. Autism Dev. Disord. 2022 , 1–15. [ Google Scholar ] [ CrossRef ]
• White, R.; Livingston, L.A.; Taylor, E.C.; Close, S.A.; Shah, P.; Callan, M.J. Understanding the contributions of trait autism and anxiety to extreme demand avoidance in the adult general population. J. Autism Dev. Disord. 2022 , 1–9. [ Google Scholar ] [ CrossRef ]
• Brown, C.M.; Stokes, M.A. Intersection of eating disorders and the female profile of autism. Psychiatr. Clin. 2020 , 43 , 735–743. [ Google Scholar ]
• Simonoff, E.; Pickles, A.; Charman, T.; Chandler, S.; Loucas, T.; Baird, G. Psychiatric disorders in children with Autism Spectrum Disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J. Am. Acad. Child Adolesc. Psychiatry 2008 , 47 , 921–929. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Barros, F.; Figueiredo, C.; Costa, A.; Soares, S.C. Sensory processing in the Autism Spectrum: The role of attention to detail and somatic trait anxiety in the olfactory perception of the general population. J. Autism Dev. Disord. 2021 , 51 , 2338–2353. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Lacroix, A.; Nalborczyk, L.; Dutheil, F.; Kovarski, K.; Chokron, S.; Garrido, M.; Gomot, M.; Mermillod, M. High spatial frequency filtered primes hastens happy faces categorization in autistic adults. Brain Cogn. 2021 , 155 , 105811. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hollin, G. From the profound to the mundane: Questionnaires as emerging technologies in autism genetics. Sci. Technol. Hum. Values 2019 , 44 , 634–659. [ Google Scholar ] [ CrossRef ]
• Nebel, M.B.; Lidstone, D.E.; Wang, L.; Benkeser, D.; Mostofsky, S.H.; Risk, B.B. Accounting for motion in resting-state fMRI: What part of the spectrum are we characterizing in Autism Spectrum Disorder? NeuroImage 2022 , 257 , 119296. [ Google Scholar ] [ CrossRef ]
• McCracken, J.T.; Anagnostou, E.; Arango, C.; Dawson, G.; Farchione, T.; Mantua, V.; McPartland, J.; Murphy, D.; Pandina, G.; Veenstra-VanderWeele, J.; et al. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. Eur. Neuropsychopharmacol. 2021 , 48 , 3–31. [ Google Scholar ] [ CrossRef ]
• Hakami, T. Efficacy and tolerability of antiseizure drugs. Ther. Adv. Neurol. Disord. 2021 , 14 , 17562864211037430. [ Google Scholar ] [ CrossRef ]
• Hakami, T. Neuropharmacology of antiseizure drugs. Neuropsychopharmacol. Rep. 2021 , 41 , 336–351. [ Google Scholar ] [ CrossRef ]
• Frye, R.E.; Casanova, M.F.; Fatemi, S.H.; Folsom, T.D.; Reutiman, T.J.; Brown, G.L.; Edelson, S.M.; Slattery, J.C.; Adams, J.B. Neuropathological mechanisms of seizures in Autism Spectrum Disorder. Front. Neurosci. 2016 , 10 , 192. [ Google Scholar ] [ CrossRef ] [ Green Version ]
• Hawkins, N.A.; Misra, S.N.; Jurado, M.; Kang, S.K.; Vierra, N.C.; Nguyen, K.; Wren, L.; George, A.L., Jr.; Trimmer, J.S.; Kearney, J.A. Epilepsy and neurobehavioral abnormalities in mice with a dominant-negative KCNB1 pathogenic variant. Neurobiol. Dis. 2021 , 147 , 105141. [ Google Scholar ] [ CrossRef ]
• De Maria, B.; Balestrini, S.; Mei, D.; Melani, F.; Pellacani, S.; Pisano, T.; Rosati, A.; Scaturro, G.M.; Giordano, L.; Cantalupo, G.; et al. Expanding the genetic and phenotypic spectrum of CHD2-related disease: From early neurodevelopmental disorders to adult-onset epilepsy. Am. J. Med. Genet. Part A 2022 , 188 , 522–533. [ Google Scholar ] [ CrossRef ]
• Cali, E.; Rocca, C.; Salpietro, V.; Houlden, H. Epileptic Phenotypes Associated with SNAREs and Related Synaptic Vesicle Exocytosis Machinery. Front. Neurol. 2021 , 12 , 806506. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Galanopoulou, A.S.; Löscher, W.; Lubbers, L.; O’Brien, T.J.; Staley, K.; Vezzani, A.; D’Ambrosio, R.; White, H.S.; Sontheimer, H.; Wolf, J.A.; et al. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward—Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open 2021 , 6 , 276–296. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Raga, S.; Specchio, N.; Rheims, S.; Wilmshurst, J.M. Developmental and epileptic encephalopathies: Recognition and approaches to care. Epileptic Disord. 2021 , 23 , 40–52. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Scheffer, I.E.; Berkovic, S.; Capovilla, G.; Connolly, M.B.; French, J.; Guilhoto, L.; Hirsch, E.; Jain, S.; Mathern, G.W.; Moshé, S.L.; et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017 , 58 , 512–521. [ Google Scholar ] [ CrossRef ]
• Fisher, R.S.; Cross, J.H.; French, J.A.; Higurashi, N.; Hirsch, E.; Jansen, F.E.; Lagae, L.; Moshé, S.L.; Peltola, J.; Roulet Perez, E.; et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017 , 58 , 522–530. [ Google Scholar ] [ CrossRef ]
• Fisher, R.S.; Acevedo, C.; Arzimanoglou, A.; Bogacz, A.; Cross, J.H.; Elger, C.E.; Engel, J., Jr.; Forsgren, L.; French, J.A.; Glynn, M.; et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia 2014 , 55 , 475–482. [ Google Scholar ] [ CrossRef ]
• Stamberger, H.; Hammer, T.B.; Gardella, E.; Vlaskamp, D.R.; Bertelsen, B.; Mandelstam, S.; de Lange, I.; Zhang, J.; Myers, C.T.; Fenger, C.; et al. NEXMIF encephalopathy: An X-linked disorder with male and female phenotypic patterns. Genet. Med. 2021 , 23 , 363–373. [ Google Scholar ] [ CrossRef ]
• Fan, H.C.; Lee, H.F.; Chi, C.S. SCN8A encephalopathy: Case report and literature review. Neurol. Int. 2021 , 13 , 143–150. [ Google Scholar ] [ CrossRef ]
• Crawford, K.; Xian, J.; Helbig, K.L.; Galer, P.D.; Parthasarathy, S.; Lewis-Smith, D.; Kaufman, M.C.; Fitch, E.; Ganesan, S.; O’Brien, M.; et al. Computational analysis of 10,860 phenotypic annotations in individuals with SCN2A-related disorders. Genet. Med. 2021 , 23 , 1263–1272. [ Google Scholar ] [ CrossRef ]
• Haddaway, N.R.; Collins, A.M.; Coughlin, D.; Kirk, S. The role of Google Scholar in evidence reviews and its applicability to grey literature searching. PLoS ONE 2015 , 10 , e0138237. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hicks, D.; Wouters, P.; Waltman, L.; De Rijcke, S.; Rafols, I. Bibliometrics: The Leiden Manifesto for research metrics. Nat. News 2015 , 520 , 429. [ Google Scholar ] [ CrossRef ] [ PubMed ]
• Hens, K.; Peeters, H.; Dierickx, K. Genetic testing and counseling in the case of an autism diagnosis: A caregivers perspective. Eur. J. Med. Genet. 2016 , 59 , 452–458. [ Google Scholar ] [ CrossRef ] [ PubMed ]

Click here to enlarge figure

Share and Cite

Lim, M.; Carollo, A.; Dimitriou, D.; Esposito, G. Recent Developments in Autism Genetic Research: A Scientometric Review from 2018 to 2022. Genes 2022 , 13 , 1646. https://doi.org/10.3390/genes13091646

Lim M, Carollo A, Dimitriou D, Esposito G. Recent Developments in Autism Genetic Research: A Scientometric Review from 2018 to 2022. Genes . 2022; 13(9):1646. https://doi.org/10.3390/genes13091646

Lim, Mengyu, Alessandro Carollo, Dagmara Dimitriou, and Gianluca Esposito. 2022. "Recent Developments in Autism Genetic Research: A Scientometric Review from 2018 to 2022" Genes 13, no. 9: 1646. https://doi.org/10.3390/genes13091646

Article Metrics

Article access statistics, further information, mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

• Latest News
• C-CAP Mentoring Initiative
• Early Career Global Reps
• GSL National Representatives
• Global Senior Leaders Map
• Nominations & Elections
• Special Interest Group (SIG)
• Anti-Racism Repository
• Author Interviews
• Global Initiatives
• President Messages
• Public Statements
• Policy Briefs
• INSAR Recognition Awards
• Slifka/Ritvo Autism Research Award
• Committee Events Calendar
• INSAR Institute
• 2025 Annual Meeting
• Annual Meeting FAQs
• Regional Meetings
• Meeting Archives
• 20th Anniversary - INSAR Annual Meeting
• Apply for Membership
• Membership FAQs
• Member Only Content
• Funding Opportunities
• Career Center
• STC Anti-Racism Repository
• Sponsorship

Remember Me

7/29/2024 Autism Research Author Interviews

4/24/2024 Latest Cultural Diversity Newsletter Out Now!

4/24/2024 Student & Trainee May 2024 Newsletter

1/8/2024 UK members employed in the profession of Autism Research can claim tax relief on their earnings.

11/21/2023 INSAR Presidential Message

INSAR is a 501(c)(3) tax-exempt organization.

• International Society for Autism Research
• 400 Admiral Blvd. | Kansas City, MO 64106
• e. [email protected]
• Create a Profile

Review Journal of Autism and Developmental Disorders

Subject Area and Category

• Psychiatry and Mental Health
• Behavioral Neuroscience
• Cognitive Neuroscience
• Developmental Neuroscience

Springer New York

Publication type

21957177, 21957185

Information

How to publish in this journal

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Evolution of the percentage of female authors.

Evolution of the number of documents cited by public policy documents according to Overton database.

Evoution of the number of documents related to Sustainable Development Goals defined by United Nations. Available from 2018 onwards.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2024. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

• Alzheimer's disease & dementia
• Arthritis & Rheumatism
• Attention deficit disorders
• Autism spectrum disorders
• Biomedical technology
• Diseases, Conditions, Syndromes
• Endocrinology & Metabolism
• Gastroenterology
• Gerontology & Geriatrics
• Health informatics
• Inflammatory disorders
• Medical economics
• Medical research
• Medications
• Neuroscience
• Obstetrics & gynaecology
• Oncology & Cancer
• Ophthalmology
• Overweight & Obesity
• Parkinson's & Movement disorders
• Psychology & Psychiatry
• Radiology & Imaging
• Sleep disorders
• Sports medicine & Kinesiology
• Vaccination
• Breast cancer
• Cardiovascular disease
• Chronic obstructive pulmonary disease
• Colon cancer
• Coronary artery disease
• Heart attack
• Heart disease
• High blood pressure
• Kidney disease
• Lung cancer
• Multiple sclerosis
• Myocardial infarction
• Ovarian cancer
• Post traumatic stress disorder
• Rheumatoid arthritis
• Schizophrenia
• Skin cancer
• Type 2 diabetes
• Full List »

share this!

September 12, 2024

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

How parents and caregivers can evaluate the research on MERT and other potential autism treatments

by Corinne Purtill, Los Angeles Times

As diagnoses of autism spectrum disorder have increased in the last two decades, so have the number of experimental and off-label therapies seeking to address the condition.

For parents navigating the complex and often contradictory landscape of autism interventions—while also balancing medical appointments, educational specialists and countless other family needs—evaluating these treatments can be daunting.

Experts in autism research talked to The Times about what parents and patients should watch for when evaluating a potential new treatment—for autism or any other condition.

Take testimonials with a grain of salt

Firsthand accounts of a therapy's life-changing effects can be powerfully compelling. But such stories alone can't indicate how effective a treatment will be for anyone else, autism experts said.

"Be wary of therapies that are sold to you with testimonials. If you go to a clinic website and they have dozens of quotes from parents saying 'This changed my child's life in XYZ ways,' that isn't the same as evidence," said Zoe Gross of the Autistic Self Advocacy Network, a nonprofit group run by and for autistic adults.

"If the main way something's advertised is through testimonials, it may be because there isn't research, or what research was done showed it wasn't effective."

Without accompanying data, there is no way to know whether any patient's experience with a treatment is typical or an outlier. A therapy could have only a 1% success rate, Gross said, and still yield dozens of positive outcomes once thousands of people have tried it.

Former patient stories can be a starting point for an exploration of whether a therapy is right for someone, doctors said, but the exploration shouldn't end there.

"There's an old saying in medicine," said Dr. Andrew Leuchter, director of UCLA's TMS Clinical and Research Service. "The plural of anecdote is not data."

Look for—and at—the research

"Right now, it's really sexy to call yourself 'evidence-based,'" said Dr. David Celiberti, executive director of the nonprofit Assn. for Science in Autism Treatment. "For a consumer, that's amazing. You hear 'evidence-based' and of course, you're going to be drawn to it. But people are using that term very loosely."

In the case of magnetic e-resonance therapy, or MERT, its developer Wave Neuroscience features on its website a library of research. Similar links feature on the sites of many licensee clinics.

Most of the publications related to autism cited by MERT clinics—and, at times, by Wave—are either limited in scope or only tangentially related to the therapy, a half-dozen experts said, including some whose work is cited.

One of them, for example, is a brief 2016 article from the Austin Journal of Autism and Related Disabilities titled "The Potential of Magnetic Resonant Therapy in Children with Autism Spectrum Disorder."

Its authors and advisors said they were surprised to learn the paper was being used to advertise the treatment. The paper contains no data or original research and concludes only that MERT could be studied further as an autism therapy without risk of serious harm.

"This isn't an evidence-based paper. It's an opinion piece about the possibilities of this technology," said Dr. John Crawford, a neurologist at Children's Hospital of Orange County and a co-author of the paper. "It's not that impactful from a scientific perspective."

Who else has verified these findings?

Many MERT clinics feature a 2014 electronic poster presentation that examines data from the charts of 141 children who received transcranial magnetic stimulation , the therapy on which MERT is based, for autism.

Until March, Wave featured the poster on its website and highlighted that 59.1% of 44 participants who completed 12 months of treatment improved their scores on the Childhood Autism Rating Scale, an assessment tool used to gauge symptom severity.

A closer look at the report shows that after five days of treatment, 38 patients were dropped from the analysis because their symptoms either showed no improvement or worsened. One had a seizure during treatment.

The authors excluded dozens more patients for various reasons. Of the remaining 44 patients, 26 saw improvement while getting the treatment. That was 59.1% of those remaining, as the poster said, but only 18.4% of the total study population.

The write-up also notes that many of those 26 children were receiving other therapies at the same time that may have been responsible for some or all of the improvements.

Posters are typically prepared as a way to highlight findings at professional conferences and "cannot be interpreted as having undergone rigorous peer review," said USC neurosurgeon Dr. Charles Liu, a co-author on the poster who is not affiliated with Wave or any MERT clinics.

"The main point of the abstract is and remains that more rigorous studies must [be] done."

If research shows changes, how do you know the therapy caused it?

Wave and licensees also highlight a 2022 paper by a technician at a licensee clinic in Australia who is also a doctoral candidate at Australia's University of the Sunshine Coast.

It looks at data from 28 patients at two MERT clinics in Australia whose brains showed "significant improvement" in their individual alpha frequency waves after treatment.

Although some previous research has found correlations between atypical alpha wave frequency and autism diagnoses, six scientists told The Times that there isn't yet enough evidence to understand how changes in alpha waves affect autistic traits, or any scientific consensus on whether "improvement" in this pattern of brain activity has any meaningful effect on autistic behaviors.

The report is a retrospective chart review, which examines existing data from patients' medical records and is often used to identify interesting outcomes worthy of further study.

By design, it does not include a control group, which is what allows researchers to identify whether any changes they see are related to the variable they are studying. Its authors noted in the paper that findings are preliminary and require further study.

"Because this was not a controlled trial or study, [the cause of the changes] could have been anything including placebo effect, any additional therapies the children were receiving, etc.," said Lindsay Oberman, director of the Neurostimulation Research Program at the National Institute of Mental Health.

Medical research follows a hierarchy of evidence. At the bottom are anecdotes and observations: valid points of information that alone aren't enough to draw broad conclusions from.

Above that are observational studies that collect and analyze preexisting data in a systematic way. And at the top are randomized controlled trials, which are designed to eliminate as much bias as possible from the experiment and ensure that the thing being studied is responsible for any changes observed.

"Families need to know that there is this gold standard for studies—to make sure that something works to help people with autism, it needs to have what's called a randomized controlled trial ," said Alycia Halladay, chief science officer at the Autism Science Foundation.

2024 Los Angeles Times. Distributed by Tribune Content Agency, LLC.

Explore further

Feedback to editors

Long-term metastatic melanoma survival dramatically improves on immunotherapy, clinical trial finds

3 hours ago

Team discovers role of ferroptosis in combating breast cancer resistance

Sep 13, 2024

Metformin found to reduce organ aging in male monkeys

Researchers discover new target for treating heart failure: Protein kinase N

RNA-sequencing study provides novel insights into chronic lymphocytic leukemia

Scientists discover potential cause of an enigmatic vascular disease primarily impacting women

Key factors identified that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications

Study finds 'supercharging' T cells with mitochondria enhances their antitumor activity

Using AI, researchers find e-cigarette brands are skirting the rules about health warning labels on Instagram

New therapy that targets and destroys tau tangles: A promising Alzheimer's disease treatment

Related stories.

Can robot-inspired computer-assisted therapy benefit children with autism?

May 15, 2024

Motor skills, sensory features differ in autism with, without ADHD

Mar 22, 2024

Adults with ADHD exhibit camouflaging behavior

Feb 21, 2024

Survey heightens concern about pandemic's impact on education of students with autism

Feb 17, 2022

Research shows in-school occupational therapy creates positive education experiences for kids with autism

Aug 16, 2023

Undiagnosed autistic traits common among youths with substance use disorders

Jan 24, 2022

Recommended for you

Study debunks theory linking autism to changes in brain's amygdala

Sep 4, 2024

Eating fish, not omega-3 supplements during pregnancy associated with lower likelihood of autism diagnosis

Sep 3, 2024

Collaborative research cracks the autism code, making the neurodivergent brain visible

Aug 28, 2024

Autistic traits, behavioral problems in 7-year-olds linked with gender nonconforming play

Study shows Dungeons and Dragons can help autistic people gain confidence and find their inner hero

Aug 27, 2024

Autism spectrum disorders linked to neurotransmitter switching in the brain

Aug 22, 2024

Let us know if there is a problem with our content

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form . For general feedback, use the public comments section below (please adhere to guidelines ).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

E-mail the story

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Newsletter sign up

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

More information Privacy policy

Donate and enjoy an ad-free experience

We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.

E-mail newsletter

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Population Study Article
• Published: 11 September 2024

Developmental screening of neurodevelopmental disorders before age 6: a nationwide health screening program

• Jong Ho Cha 1 ,
• Soorack Ryu 2 ,
• Minjung Park 3 ,
• Byung Chan Lim 1 ,
• Yong Joo Kim 4 &
• Jin-Hwa Moon 5 , 6  

Pediatric Research ( 2024 ) Cite this article

14 Accesses

Metrics details

We aimed to investigate the association between developmental screening before 24 months of age and neurodevelopmental disorders (NDDs) at 4–6 years of age.

We included 922,899 newborn born between 2014 and 2016 registered in National Health Insurance Service (NHIS). Developmental screening was administered at 9–12 and 18–24 months old with the Korean Developmental Screening Test for Infants & Children (K-DST). Diagnoses of NDDs was based on the World Health Organization’s International Classification of Diseases, Tenth Revision (ICD-10), provided by the NHIS database.

Among 637,277 individuals who underwent screening at 9–12 and 18–24 months, Screen-positivity (defined as summed score < −2 standard deviation) for gross motor domain at 9–12 months was significantly associated with the incidence of autism spectrum disorder (aHR, 2.24; 95% CI, 1.80–2.80) and cerebral palsy (aHR, 4.81; 95% CI, 3.62–6.38). Screening positive at language domain at 18–24 months old was associated with autism spectrum disorder (aHR 5.50; 95% CI, 4.31– 7.02) and developmental language disorder (aHR 8.67; 95% CI, 7.27–10.33) at 4–6 years of age.

Widespread nationwide implementation of screening programs before 24 months was effective in identifying NDDs at 4–6 years of age. Further strategies integrating with referral and intervention systems should be established.

We investigated the screening effect of nationwide developmental screening program on neurodevelopmental disorders using nationwide data.

Gross motor delay during infancy was significant predictor of later neurodevelopmental disorders.

Language, cognitive, and social delay before 24 months of age was associated with later autism spectrum disorders and developmental language disorders.

Widespread nationwide implementation of screening programs before 24 months was effective in identifying NDDs at 4–6 years of age and should be encouraged.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 14 print issues and online access

251,40 € per year

only 17,96 € per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Clinical Characteristics of Developmentally Delayed Children based on Interdisciplinary Evaluation

Examination of psycho-motor development of children who were 6–36 months in the COVID-19 stay-at-home period

The effect of gestational age on major neurodevelopmental disorders in preterm infants

Data availability.

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Gyllenberg, D. et al. Temporal changes in the incidence of treated psychiatric and neurodevelopmental disorders during adolescence: an analysis of two national Finnish birth cohorts. Lancet Psychiatry 5 , 227–236 (2018).

Article   PubMed   Google Scholar  

Zablotsky, B. et al. Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. Pediatrics 144 , e20190811 (2019).

Cheong, J. L. et al. Temporal trends in neurodevelopmental outcomes to 2 years after extremely preterm birth. JAMA Pediatr. 175 , 1035–1042 (2021).

Rah, S. S., Hong, S.-B. & Yoon, J. Y. Prevalence and incidence of developmental disorders in Korea: a nationwide population-based study. J. Autism Dev. Disord. 50 , 4504–4511 (2020).

Thapar, A., Cooper, M. & Rutter, M. Neurodevelopmental disorders. Lancet Psychiatry 4 , 339–346 (2017).

Cioni, G., Inguaggiato, E. & Sgandurra, G. Early intervention in neurodevelopmental disorders: underlying neural mechanisms. Dev. Med. Child Neurol. 58 , 61–66 (2016).

Lipkin, P. H. et al. Promoting optimal development: identifying infants and young children with developmental disorders through developmental surveillance and screening. Pediatrics 145 , e20193449 (2020).

Hyman, S. L. et al. identification, evaluation, and management of children with autism spectrum disorder. Pediatrics 145, e20193447 (2020).

Hirai, A. H., Kogan, M. D., Kandasamy, V., Reuland, C. & Bethell, C. Prevalence and variation of developmental screening and surveillance in early childhood. JAMA Pediatr. 172 , 857–866 (2018).

Article   PubMed   PubMed Central   Google Scholar  

Charkaluk, M.-L. et al. Ages and stages questionnaire at 3 years for predicting IQ at 5–6 years. Pediatrics 139 , e20162798 (2017).

KOSIS. Birth Statistics; Live Births by Sex and Month for City, County, and District .

Chung, H. J. et al. Development of the Korean developmental screening test for infants and children (K-Dst). Clin. Exp. Pediatr. 63 , 438 (2020).

Kim, D. et al. Korean developmental screening test for infants and children (K-Dst): development, applications, and implications for future early childhood development interventions. Clin. Exp. Pediat. 66 , 288 (2023).

Article   Google Scholar  

Jang, C. H. et al. Clinical usefulness of the Korean developmental screening test (K-Dst) for developmental delays. Ann. Rehabil. Med. 43 , 490 (2019).

Hagberg, K. W. & Jick, S. S. Validation of autism spectrum disorder diagnoses recorded in the clinical practice research datalink, 1990–2014. Clin. Epidemiol. , 9 , 475–482 (2017).

Carlsson, T., Molander, F., Taylor, M. J., Jonsson, U. & Bölte, S. Early environmental risk factors for neurodevelopmental disorders–a systematic review of twin and sibling studies. Dev. Psychopathol. 33 , 1448–1495 (2021).

Schieve, L. A. et al. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, national health interview survey, 2006–2010. Res. Dev. Disabil. 33 , 467–476 (2012).

Sadowska, M., Sarecka-Hujar, B. & Kopyta, I. Cerebral palsy: current opinions on definition, epidemiology, risk factors, classification and treatment options. Neuropsychiatr. Dis. Treat. , 16 , 1505–1518 (2020).

Fernald, A., Marchman, V. A. & Weisleder, A. Ses differences in language processing skill and vocabulary are evident at 18 months. Dev. Sci. 16 , 234–248 (2013).

Potijk, M. R., Kerstjens, J. M., Bos, A. F., Reijneveld, S. A. & de Winter, A. F. Developmental delay in moderately preterm-born children with low socioeconomic status: risks multiply. J. Pediatr. 163 , 1289–1295 (2013).

Hoff, E. The specificity of environmental influence: socioeconomic status affects early vocabulary development via maternal speech. Child Dev. 74 , 1368–1378 (2003).

Mesman, J., van IJzendoorn, M. H. & Bakermans‐Kranenburg, M. J. Unequal in opportunity, equal in process: parental sensitivity promotes positive child development in ethnic minority families. Child Dev. Perspect. 6 , 239–250 (2012).

Rai, D. et al. Parental socioeconomic status and risk of offspring autism spectrum disorders in a Swedish population-based study. J. Am. Acad. Child Adolesc. Psychiatry 51 , 467–476.e466 (2012).

Yu, T., Lien, Y.-J., Liang, F.-W. & Kuo, P.-L. Parental socioeconomic status and autism spectrum disorder in offspring: a population-based cohort study in Taiwan. Am. J. Epidemiol. 190 , 807–816 (2021).

Zumach, A., Gerrits, E., Chenault, M. & Anteunis, L. Long-term effects of early-life otitis media on language development. J. Speech Lang. Hear. Res. 53 , 34–43 (2010).

Ewen, J. B., Marvin, A. R., Law, K. & Lipkin, P. H. Epilepsy and autism severity: a study of 6,975 children. Autism Res. 12 , 1251–1259 (2019).

Micai, M. et al. Early behavioral markers for neurodevelopmental disorders in the first 3 years of life: an overview of systematic reviews. Neurosci. Biobehav. Rev. 116 , 183–201 (2020).

Harris, S. R. Early motor delays as diagnostic clues in autism spectrum disorder. Eur. J. Pediatr. 176 , 1259–1262 (2017).

Ming, X., Brimacombe, M. & Wagner, G. C. Prevalence of motor impairment in autism spectrum disorders. Brain Dev. 29 , 565–570 (2007).

Lemcke, S., Juul, S., Parner, E. T., Lauritsen, M. B. & Thorsen, P. Early signs of autism in toddlers: a follow-up study in the Danish national birth cohort. J. Autism Dev. Disord. 43 , 2366–2375 (2013).

Libertus, K., Sheperd, K. A., Ross, S. W. & Landa, R. J. Limited fine motor and grasping skills in 6‐month‐old infants at high risk for autism. Child Dev. 85 , 2218–2231 (2014).

Provost, B., Lopez, B. R. & Heimerl, S. A comparison of motor delays in young children: autism spectrum disorder, developmental delay, and developmental concerns. J. Autism Dev. Disord. 37 , 321–328 (2007).

Ghassabian, A. et al. Gross motor milestones and subsequent development. Pediatrics 138 , e20154372(2016).

van Batenburg-Eddes, T. et al. Early infant neuromotor assessment is associated with language and nonverbal cognitive function in toddlers: the generation r study. J. Dev. Behav. Pediatr. 34 , 326–334 (2013).

Nishitani, N., Schurmann, M., Amunts, K. & Hari, R. Broca’s region: from action to language. Physiology 20 , 60–69 (2005).

Willems, R. M. & Hagoort, P. Neural evidence for the interplay between language, gesture, and action: a review. Brain Lang. 101 , 278–289 (2007).

Ridler, K. et al. Fronto-cerebellar systems are associated with infant motor and adult executive functions in healthy adults but not in schizophrenia. Proc. Natl Acad. Sci. 103 , 15651–15656 (2006).

Article   CAS   PubMed   PubMed Central   Google Scholar  

Beacham, C. et al. Screening for autism spectrum disorder: profiles of children who are missed. J. Dev. Behav. Pediatr 39 , 673–682 (2018).

Hardy, S., Haisley, L., Manning, C. & Fein, D. Can screening with the ages and stages questionnaire detect autism? J. Dev. Behav. Pediatr. 36 , 536 (2015).

Download references

Acknowledgements

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : RS-2023-00267049). The authors would like to thank Young-Jin Choi and Jae Yoon Na, Department of Pediatrics, Hanyang University for their assistance with data acquisition.

Author information

Authors and affiliations.

Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea

Jong Ho Cha & Byung Chan Lim

Biostatistical Consulting and Research Lab, Medical Research Collaborating Center, Hanyang University, Seoul, Korea

Soorack Ryu

Department of Pediatrics, Korea University Anam Hospital, Seoul, Korea

Minjung Park

Division of Pediatric Gastroenterology, Department of Pediatrics, Hanyang University College of Medicine, Seoul, Korea

Yong Joo Kim

Department of Pediatrics, Hanyang University Guri Hospital, Guri, Korea

Jin-Hwa Moon

Division of Pediatric Neurology, Department of Pediatrics, Hanyang University College of Medicine, Seoul, Korea

You can also search for this author in PubMed   Google Scholar

Contributions

J.H.C. designed the study, drafted the initial manuscript, carried out the initial analyses. S.R. conceived and designed the study, collected and analyzed the data. M.P. reviewed the data analyses and drafted the initial manuscript. B.C.L. critically reviewed the data analyses and the manuscript. Y.J.K. critically reviewed the data analyses and the manuscript. J.-H.M. designed the study, critically reviewed and revised the manuscript.

Corresponding author

Correspondence to Jin-Hwa Moon .

Ethics declarations

Competing interests.

The authors declare no competing interests.

Patient consent

Patient consent was waived as public data from the NHIS were used.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary tables, rights and permissions.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Cite this article.

Cha, J.H., Ryu, S., Park, M. et al. Developmental screening of neurodevelopmental disorders before age 6: a nationwide health screening program. Pediatr Res (2024). https://doi.org/10.1038/s41390-024-03516-6

Download citation

Received : 21 March 2024

Revised : 05 August 2024

Accepted : 12 August 2024

Published : 11 September 2024

DOI : https://doi.org/10.1038/s41390-024-03516-6

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies